#  @larrywabrams Lawrence W. Abrams Lawrence W. Abrams posts on X about cvs, $cvs, $chrs, $ci the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::211614337/interactions)  - [--] Week [---] -87% - [--] Month [------] +826% - [--] Months [------] -13% - [--] Year [------] -26% ### Mentions: [--] [#](/creator/twitter::211614337/posts_active)  ### Followers: [-----] [#](/creator/twitter::211614337/followers)  - [--] Week [-----] +0.10% - [--] Month [-----] +0.87% - [--] Months [-----] -2.20% - [--] Year [-----] -1.80% ### CreatorRank: undefined [#](/creator/twitter::211614337/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [technology brands](/list/technology-brands) [cryptocurrencies](/list/cryptocurrencies) [countries](/list/countries) [social networks](/list/social-networks) [celebrities](/list/celebrities) [currencies](/list/currencies) [automotive brands](/list/automotive-brands) [travel destinations](/list/travel-destinations) **Social topic influence** [cvs](/topic/cvs), [$cvs](/topic/$cvs), [$chrs](/topic/$chrs), [$ci](/topic/$ci) #36, [$alvo](/topic/$alvo), [$wba](/topic/$wba), [$rad](/topic/$rad), [$googl](/topic/$googl), [insurance](/topic/insurance), [$amzn](/topic/$amzn) **Top accounts mentioned or mentioned by** [@ftc](/creator/undefined) [@stanmehr](/creator/undefined) [@costplusdrugs](/creator/undefined) [@bmadden4](/creator/undefined) [@mattbiotech](/creator/undefined) [@cvshealth](/creator/undefined) [@qniatof](/creator/undefined) [@stocksdd](/creator/undefined) [@sherman1890](/creator/undefined) [@truepillrx](/creator/undefined) [@daytonpubpolicy](/creator/undefined) [@sandozglobal](/creator/undefined) [@drugchannels](/creator/undefined) [@mintzlaw](/creator/undefined) [@biohazard3737](/creator/undefined) [@bengolub](/creator/undefined) [@hashgraph](/creator/undefined) [@d1fund](/creator/undefined) [@stevewagsinvest](/creator/undefined) [@rabbiwolpe](/creator/undefined) **Top assets mentioned** [CVS Health Corp (CVS)](/topic/cvs) [Cigna Corp (CI)](/topic/$ci) [Alvotech Ordinary Shares (ALVO)](/topic/$alvo) [Walgreens Boots Alliance Inc (WBA)](/topic/$wba) [Radworks (RAD)](/topic/$rad) [Alphabet Inc Class A (GOOGL)](/topic/$googl) [Amazon.com, Inc. (AMZN)](/topic/$amzn) [Dutch Bros, Inc. (BROS)](/topic/$bros) [Amgen, Inc. (AMGN)](/topic/$amgn) [Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)](/topic/$teva) [Eli Lilly and Company (LLY)](/topic/$lly) [AbbVie Inc (ABBV)](/topic/$abbv) [UnitedHealth Group (UNH)](/topic/$unh) [McKesson Corporation (MCK)](/topic/$mck) [GoodRx Holdings, Inc. (GDRX)](/topic/$gdrx) [Pfizer, Inc. (PFE)](/topic/$pfe) [Apple, Inc. (AAPL)](/topic/$aapl) [Microsoft Corp. (MSFT)](/topic/$msft) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Walmart, Inc. (WMT)](/topic/$wmt) [Marvell Technology Inc (MRVL)](/topic/$mrvl) [Cencora, Inc. (COR)](/topic/$cor) [Novartis AG (NVS)](/topic/$nvs) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Lithium (LITH)](/topic/lithium) [Novo-Nordisk (NVO)](/topic/$nvo) [Moon Tropica (CAH)](/topic/$cah) [Origin Protocol (OGN)](/topic/$ogn) [The Bancorp Inc. (TBBK)](/topic/$tbbk) [NVIDIA Corp. (NVDA)](/topic/$nvda) [Bitcoin (BTC)](/topic/bitcoin) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Synthetify (SNY)](/topic/$sny) [RELX PLC (RELX)](/topic/$relx) ### Top Social Posts Top posts by engagements in the last [--] hours "@FTC about to settle with #PBMs $CI ESI in insulin list price collusion case -- Weak due #SCOTUS ruling in Twombly (2007) that parallel conduct alone insufficient for antitrust liability. To avoid summary judgement against plaintiff must prove overt agreement to collude is plausible not merely possible. Need "smoking gun" emails among CEOs in [----] to collude. See my paper 🔽 https://twitter.com/i/web/status/2014825810922995767 https://twitter.com/i/web/status/2014825810922995767" [X Link](https://x.com/larrywabrams/status/2014825810922995767) 2026-01-23T22:21Z [----] followers, [---] engagements "@ElysiumEffect $MSFT Maia [---] announcement 8:01 AM. $MRVL spike 8:00 AM" [X Link](https://x.com/larrywabrams/status/2015854699984060628) 2026-01-26T18:29Z [----] followers, [---] engagements "@FTC collusion case against Big [--] #pbms $CI $CVS $UNH and Big [--] insulin mfg $NVO $LLY $SNY weak as parallel list pricing along insufficient for "unfairness" or antitrust liability. Need "smoking gun" evidence of explicit emails among CEOs in [----] (see my article pin-pointing this date. 🔽 https://twitter.com/i/web/status/2016992232184930476 https://twitter.com/i/web/status/2016992232184930476" [X Link](https://x.com/larrywabrams/status/2016992232184930476) 2026-01-29T21:49Z [----] followers, [---] engagements "This generations PayPal mafia picture. $NVDA $TSMC $MU Taiwan AI supply chain in one picture. https://t.co/ueTPDXnsRP AI supply chain in one picture. https://t.co/ueTPDXnsRP" [X Link](https://x.com/larrywabrams/status/2017659208666411137) 2026-01-31T18:00Z [----] followers, [---] engagements "@MostroGrowth Some uncertainty over whether $MRVL can be a supplier to both $MSFT and $AMZN . Maybe best go all in with one" [X Link](https://x.com/larrywabrams/status/2018099345909067778) 2026-02-01T23:09Z [----] followers, [---] engagements "New #meme word "orchestrator" as in "I am good at orchestrating my kids' Saturday schedule" or "I need you to better orchestrate dinner honey" #ai #code #Software" [X Link](https://x.com/anyuser/status/2018801592599011359) 2026-02-03T21:39Z [----] followers, [--] engagements "@semivision_tw What companies will benefit and what period [----] [----] Vs after $MRVL Coherent Lightmatter" [X Link](https://x.com/larrywabrams/status/2019087371254325544) 2026-02-04T16:35Z [----] followers, [---] engagements "$AMZN moving to partner with OpenAI on models inevitably leading to EXCLUSIVE use of their agents within their shopping walled garden sets up antitrust Sherman [--] and [--] down the road not to mention agency issues" [X Link](https://x.com/anyuser/status/2019117795934630156) 2026-02-04T18:36Z [----] followers, [---] engagements "@Mr_Derivatives @grok summarize @Mr_Derivatives stock calls for past two weeks compared to what price is now" [X Link](https://x.com/larrywabrams/status/2019241262277447927) 2026-02-05T02:46Z [----] followers, [--] engagements "@danielisdizzy @grok compare @danielisdizzy stock picks from January [--] [----] to February [--] [----] with the price they are at now with % change" [X Link](https://x.com/larrywabrams/status/2019243320082591837) 2026-02-05T02:54Z [----] followers, [--] engagements "Call it The Saylor Contagion : A major buyer of $MSFT convertible debt is Calamos Investments with a number of bitcoin backed EFT. Watch run to liquidate these EFTs halted by Calamos triggering run to withdraw from other funds / financial institutions remotely associated with bitcoin. $BTC https://twitter.com/i/web/status/2019546873414156788 https://twitter.com/i/web/status/2019546873414156788" [X Link](https://x.com/larrywabrams/status/2019546873414156788) 2026-02-05T23:01Z [----] followers, [---] engagements "Call it The Saylor Contagion : A major buyer of $MSTR convertible debt is Calamos Investments with a number of bitcoin backed EFT. Watch run to liquidate these EFTs halted by Calamos triggering run to withdraw from other funds / financial institutions remotely associated with bitcoin. $BTC https://twitter.com/i/web/status/2019575959922569723 https://twitter.com/i/web/status/2019575959922569723" [X Link](https://x.com/larrywabrams/status/2019575959922569723) 2026-02-06T00:56Z [----] followers, [---] engagements "Ad in current issue of @NewYorker by $BMY touting checkpoint inhibitor combo of PD-1 Opdivo + CTLA-4 YERVOY. INHO $BMY desperately needs a safe synergistic second gen CD47 from $TRIL to go with Opdivo not a CTLA-4 with serious side effects" [X Link](https://x.com/anyuser/status/1277807118540632069) 2020-06-30T03:32Z [----] followers, [--] engagements "2026 prediction: drug distributors $COR $CAH $MCK planning to carve out combined Rx healthcare benefit driven in part by biologic infusions (covered by medical benefit) now producing close substitute (newly patented) self-injectables (now covered by #PBMs benefit). A threat to $CVS $UNH $CI https://twitter.com/i/web/status/2018806505907331286 https://twitter.com/i/web/status/2018806505907331286" [X Link](https://x.com/anyuser/status/2018806505907331286) 2026-02-03T21:59Z [----] followers, [---] engagements "@PhotonCap Can you map the same partners in OCS for $MSFT $NVDA $AMZN" [X Link](https://x.com/larrywabrams/status/2019093799478427952) 2026-02-04T17:00Z [----] followers, [---] engagements "$CI #PBMs unit Express Scripts just settled insulin collusion case with @FTC . At glance looks like ESI reseller margins would take a big hit yet Wall Street doesnt see it that way maybe too early🙁" [X Link](https://x.com/anyuser/status/2019105040343220340) 2026-02-04T17:45Z [----] followers, [---] engagements "@costplusdrugs and $GDRX - cash pay retail and mail order Rx- losers in @FTC settlement with $CI #pbms ESI moving to coinsurance and copays based on net prices not gross retail prices" [X Link](https://x.com/larrywabrams/status/2019115517404148029) 2026-02-04T18:27Z [----] followers, [---] engagements "@FTC settlement with #PBMs ESI unit of $CI basically changes biz model -- still opaque -- from rebates and spread pricing to % fee based on each net priced Rx aggregated to PMPY trend. Given ESI ok with it I estimate new biz model at same 8% gross profit margin but now % of PMPY = $190 PMPY fee equivalent at [----] trend of around $2370 1/n https://twitter.com/i/web/status/2019138070931759553 https://twitter.com/i/web/status/2019138070931759553" [X Link](https://x.com/anyuser/status/2019138070931759553) 2026-02-04T19:56Z [----] followers, [---] engagements "@PhotonCap I found these OCS partners listed on $NVDA page. Problem I find as investor is estimating timeline of actual ramp up of OCS by big [--] $MST $NVDA $AMZN . Looks like [--] years at least before any P&L impact smaller partners" [X Link](https://x.com/larrywabrams/status/2019158405697663351) 2026-02-04T21:17Z [----] followers, [----] engagements "Up next after #Anthropic provides #AI alternative to Lexis/Nexis $RELX is government antiquated PACER . Indeed all government provided UX to data is up for disruption . 👍" [X Link](https://x.com/anyuser/status/2021290992369008924) 2026-02-10T18:31Z [----] followers, [---] engagements "Apparently a thing at Columbu Ohio weddings - #osu #BuckeyePride" [X Link](https://x.com/larrywabrams/status/1951803530844786872) 2025-08-03T00:33Z [----] followers, [---] engagements "Some thoughts on pending @FTC and $CI Express Scripts #PBMs settlement: a containment win for ESI limiting remedy to best effort to negotiate low list prices on legacy insulin drugs and no spread pricing on same drugs. No general remedy for opaque reseller business models now dependent on renamed formulary fees instead of rebates https://twitter.com/i/web/status/2014412178036818043 https://twitter.com/i/web/status/2014412178036818043" [X Link](https://x.com/larrywabrams/status/2014412178036818043) 2026-01-22T18:57Z [----] followers, [---] engagements "@SanCompounding Can you explain difference in PE (2026) $MRVL vs $ALAB Marvell ( $MRVL ) -8% YTD PE(2026): 27.7x Astera Labs ( $ALAB ) -9% YTD PE(2026): 64.1x" [X Link](https://x.com/larrywabrams/status/2018392354227728608) 2026-02-02T18:33Z [----] followers, [---] engagements "Maybe its because recent years PMPY trend driven more by utilization- especially GLP-1 and biologics - not net prices - #PBMs formulary management more about step therapy exclusions PA than rebate negotiations. $CI ESI willing to settle @FTC as rebates matter much less" [X Link](https://x.com/larrywabrams/status/2019107045904117800) 2026-02-04T17:53Z [----] followers, [---] engagements "Now copayment and coinsurence based on net prices reduces payments to plan sponsors. I guestimate this could amount to as much as 2% PMPY trend = $47 PMPY. Not small potatoes given total ffe equivalent of PMPY payments to #PBMs is 8% = 25% of ffs equivalent paid Plus less copay = more utilization = more plan sponsor costs 2/n" [X Link](https://x.com/larrywabrams/status/2019140339362304461) 2026-02-04T20:05Z [----] followers, [---] engagements "Still opaque $CI #pbms Express Scripts biz model move to % fees based on net prices which aggregates to % PMPY trend shifts #PBMs advocaries from #Pharma and drugstores to plan sponsors who won't like loss of copays and higher and higher PMPY trend 3/n" [X Link](https://x.com/larrywabrams/status/2019141759071351114) 2026-02-04T20:11Z [----] followers, [---] engagements "Per @drugchannels #PBMs recent PMPY trend driven by utilization not net prices -- mostly GLP-1 and self-injectable biologics. Expect 14% YoY PMPY trend to continue now net price based lower copays and #Pharma offering self-injectable alternative to medical benefit infusions for Remicade Humira Keytruda. 4/n" [X Link](https://x.com/larrywabrams/status/2019146967809741120) 2026-02-04T20:32Z [----] followers, [---] engagements "Significant $CI ESI #PBMs first to settle insulin collusion case with @FTC In some ways strongest of Big [--] #PBMs to weather any instability in transition of one opaque biz model -- retained rebates spread pricing -- to another- "data" "price protection" "placement" formulary fees expressed as a % of net prices (instead of % off WAC) aggregated to PMPY trend 5/n https://twitter.com/i/web/status/2019148298171609487 https://twitter.com/i/web/status/2019148298171609487" [X Link](https://x.com/larrywabrams/status/2019148298171609487) 2026-02-04T20:37Z [----] followers, [---] engagements "@DrugChannels @FTC Big [--] killer move by $CI #PBMs ESI to offer 2027-8 -- transparent FFS biz model around $250 PMPY with trend guarantees and variance gain and loss sharing. See my PBM insurance biz model paper on this 🔽 6/n" [X Link](https://x.com/anyuser/status/2019150160631304298) 2026-02-04T20:44Z [----] followers, [---] engagements "Nice summary by @Mintz_Law of proposed DoL #PBMs fee disclosure rule for employer self-insured plans -- will accelerate move toward full insurance biz model -- either MLR or FFS with PMPY trend guarantees. See my paper on this 🔽 https://t.co/TjsU8MFvJb #PBMS #health #labor @Mintz_Law https://t.co/ZHThB4XNVZ https://t.co/TjsU8MFvJb #PBMS #health #labor @Mintz_Law https://t.co/ZHThB4XNVZ" [X Link](https://x.com/anyuser/status/2021387113527378146) 2026-02-11T00:53Z [----] followers, [---] engagements "@matthewherper If #Pharma and Wall Street believed that Trump is going to actually sign an EO for International Reference Pricing In #PartB biotech stock index $IBI would be down 10%. Instead Trump just posing to get Pharma to donate more to re-election campaign" [X Link](https://x.com/larrywabrams/status/1147234295129370624) 2019-07-05T20:02Z [----] followers, [--] engagements "$CHRS will have a new #biosimilar competition from $NVS Sandoz. Will have to fight very hard to reach and maintain a 20% share. IMHO [----] revenue will not exceed $500M with flat QtoQ revenue after Q1. Stock is fairly priced now According to Biocentury @Sandoz's WAC price for #Ziextenzo will be $3925 approximately 9% less than that for #Udenyca and #Fulphila and 37% below #Neulasta's WAC. #biosimilars https://t.co/0qtaQ0Yv8C According to Biocentury @Sandoz's WAC price for #Ziextenzo will be $3925 approximately 9% less than that for #Udenyca and #Fulphila and 37% below #Neulasta's WAC." [X Link](https://x.com/larrywabrams/status/1195369301911298049) 2019-11-15T15:53Z [----] followers, [--] engagements "1/2 While CTLA-4 still leads combo trials with PD-1/L1 the toxicity of Yervoy has caused the leaders -- $MRK $BMY $RHHY $AZN -- to look for new combos -- CD47 and TIGIT -- That's why $GILD called its acquisition of $FTSV "foundational" The future is bright for $TRIL $CGEN" [X Link](https://x.com/larrywabrams/status/1262092097756127232) 2020-05-17T18:46Z [----] followers, [--] engagements "$CHRS not good that CFO resigns effective 3-7 then appoints communications guy. Likely due to terrible QoQ net sales decline which I have forecasted at 18.2% due to #pegfilgristim #biosimilar pricing pressure from new entrants $NVS (Sandoz) and $PFE [----] will be bad" [X Link](https://x.com/larrywabrams/status/1362147651412586496) 2021-02-17T21:11Z [----] followers, [--] engagements "$SHMP up 20% in [--] days. IMHO NASDAQ listing within 2-3 weeks which makes it eligible for listings on StockTwits buying on Robinhood investing by micro cap funds. Fully grown shrimp for sale in 4Q21. More upside potential than $AASZF and $AQB" [X Link](https://x.com/larrywabrams/status/1405307028935872512) 2021-06-16T23:31Z [----] followers, [--] engagements "@Biohazard3737 @PreparedRemarks @tomicki Characterizing $CHRS as adapting to market 2018-2021. I would call transition from Made In America value priced Udencya to China trial / China licensed late entrants checkpoint inhibitors a COMPLETE ABOUT FACE" [X Link](https://x.com/larrywabrams/status/1482463235706077190) 2022-01-15T21:22Z [----] followers, [--] engagements "@Biohazard3737 @PreparedRemarks @tomicki Instead of your view of buying $CHRS now a cheap CALL option on multiple billion dollar PD-1 market I could see it as a PUT option on FDA rejection of BLAs based on poorly designed China only trials" [X Link](https://x.com/larrywabrams/status/1482464299935277060) 2022-01-15T21:26Z [----] followers, [--] engagements "@Sanctuary_Bio $GILD not doing great with its oncology acquisitions $FTSV CD47 checkpoint inhibitor and $KITE autologous CAR-T Yescarta. Up next maybe is NK cell therapy $FATE $GMDA or preclinical $IPSC and $CELU Ha Ha for what they paid for $KITE they could buy all 4" [X Link](https://x.com/larrywabrams/status/1486195036517806080) 2022-01-26T04:31Z [----] followers, [--] engagements "$AMZM purchase of One Medical is all about software and synergies: Watch them threaten Big [--] #PBMs by rolling out a narrow network pharmacy benefit where narrow is One Med Drs driving PMPY drug spend 20% below Big [--] or about $850 PMPY" [X Link](https://x.com/larrywabrams/status/1550166042395099136) 2022-07-21T17:09Z [----] followers, [--] engagements "@chrissyfarr $AMZM purchase of One Medical is all about software and synergies: Watch them threaten Big [--] #PBMs by rolling out a narrow network pharmacy benefit where narrow is One Med Drs driving PMPY drug spend 20% below Big [--] or about $850 PMPY" [X Link](https://x.com/larrywabrams/status/1550189101671780353) 2022-07-21T18:40Z [----] followers, [--] engagements "Like Rocky and Adrian $CHRS selling Lucentis biosimilar Cimerli to $SDZNY (Sandoz) "fills each other's gaps" = $CHRS fills cash gap Sandoz fills pipeline gap with anti-VEGF drug to sell now and could save $100M in R&D by dropping own development Avastin & Eylea #biosimilars" [X Link](https://x.com/larrywabrams/status/1749532588048601507) 2024-01-22T20:40Z [----] followers, [----] engagements "Watch in a year $CHRS and $SDZNY (Sandoz) do a another "fills each other's gaps" deal where $CHRS fills cash gap again by selling its complete Udenyca array of injectables for say $250M+. Sandoz fills OBI gap in pegfilgrastim offerings now only with in-office infusion Ziextenzo" [X Link](https://x.com/larrywabrams/status/1749537023986483589) 2024-01-22T20:58Z [----] followers, [---] engagements "Another 2nd guessing Landfear tweet: $CHRS core competency is its marketing team's ability to gain great market share in the Dr assisted buy & bill markets across diverse #biosismilars. Why pivot to Rx self-injectables Humira and PD-1 Tori Why not stay the course with Stelara" [X Link](https://x.com/larrywabrams/status/1750333951250677836) 2024-01-25T01:45Z [----] followers, [---] engagements "I'll answer my own question: $CRHS CEO big ego drove him put addressable market over core competency as #1: Humira market $21B in [----] PD-1 market they say will be $139 B in [----]. Whereas Lucentis market was only $2.1 B in [----] and Stelara market will be about $10.5 B" [X Link](https://x.com/larrywabrams/status/1750335738124943451) 2024-01-25T01:52Z [----] followers, [---] engagements "In [----] $ABBV still had Humira 95%+ share and $12B net revenue despite #biosimilars . Maybe one from $AMGN $ALVO $OGN $CHRS $SDZNY will get 10% of est $10B [----] and $8B [----]. Rest are 2% ers -- $200M in [----] and $160M in [----] market. There will be a lot of disappointed investors" [X Link](https://x.com/larrywabrams/status/1754306394868863297) 2024-02-05T00:50Z [----] followers, [----] engagements "In the future could $CVS continue to private label reference drugs losing patent protection -- Enbrel Prolia Zolair -- invoking interchangeable thereby earning mfg markups while denying rebates to Optum and ESI whenever a reference still covered by Optum and ESI comes in" [X Link](https://x.com/larrywabrams/status/1755392090719264879) 2024-02-08T00:44Z [----] followers, [---] engagements "Also anyone know about the legality of "backwards" interchangeability - pharmacists exchanging a lower cost reference like a $CVS Codavis private label Humira for an Rx for #biosimilars like $SDZNY Hyrimoz or BI's Cyltezo or $AMGN Amjevita @StanMehr" [X Link](https://x.com/larrywabrams/status/1755397264993075660) 2024-02-08T01:04Z [----] followers, [---] engagements "The issue of safety and USA reliance on China #biosimilar CMOs like WuXi Biologics begs the question of who is $CHRS CMO for Humira biosimilar Yusimry Their 10-K recognizes risks of CMOs but is not specific. Name of CMO inspected for BLA for CHS-1420(Yusimry) is redacted" [X Link](https://x.com/larrywabrams/status/1765449321305243800) 2024-03-06T18:48Z [----] followers, [---] engagements "@avidresearch Given Humira at time was HC why in early days of planning 2018-19 some cos choose HC ( $SDZNY $ALVO ) while other chose LC ( $AMGN $CHRS BI ) What was $CHRS thinking A slam dunk I guess given as late as Nov [----] still projecting 1.2B revenue in 2026" [X Link](https://x.com/larrywabrams/status/1788653528191570071) 2024-05-09T19:33Z [----] followers, [---] engagements "@MattJMcClintock Should compare traffic at dedicated cosmetics stores: Sephora vs $ULTA or any front of store at a drug store chain" [X Link](https://x.com/larrywabrams/status/1795699290603721001) 2024-05-29T06:10Z [----] followers, [----] engagements "@minchoi I took Its over metaphorically to mean AI saying Its over to Hollywood. NOT. AI at sunday comic strip stage. Long way to go before a full length movie with compelling plot twists and actors/ actresses" [X Link](https://x.com/larrywabrams/status/1829578106795106318) 2024-08-30T17:53Z [----] followers, [----] engagements "12000 sq ft drugstore model is obsolete. Witness decline of $WBA $CVS $RAD retail. Future of Rx retail is cheap land converted to drive-in + tele-pharmacist from mobile phone + robot delivery. Also watch #PBMs sell off retail Rx claims adjudication to distributors $COR $MCK $CAH https://twitter.com/i/web/status/1875229370274767160 https://twitter.com/i/web/status/1875229370274767160" [X Link](https://x.com/larrywabrams/status/1875229370274767160) 2025-01-03T17:14Z [----] followers, [----] engagements "Why is $ALVO down 7.4% so far today IMHO it is a reaction to a Formycon PR that it will take about a $100 Million balance sheet write down of its purchase of a biosimilar to Stelara due to now perceived intense rebate competition off WAC for #PBMs formulary positions. This implies $ALVO projected net revenue from its own Stelara biosimilar SELARSDI is way too high" [X Link](https://x.com/larrywabrams/status/1892297257804059088) 2025-02-19T19:36Z [----] followers, [---] engagements "No. Always danger of short squeeze due to 63% of outstanding stock owned by holding companies controlled by $ALVO founder Robert Wiseman former CEO of Actavis. Their self-injectable #biosimilars partnership with $TEVA is falling way short due to intense competition for #PBMs favored formulary positions. Humira biosimilar - failure. Upcoming Stelara biosimilar -- will have to compete with [--] others" [X Link](https://x.com/larrywabrams/status/1892308788126110123) 2025-02-19T20:22Z [----] followers, [---] engagements "$ALVO besides LT debt of $960M it has LT debt of $530.5 M in "Derivative Financial Liabilities" These are bond bondholder warrants to convert to stock $10 and pre-IPO stock holders warrants to purchase stock anytime after [--] days stock $15. GAAP demands liability still on books but 😂 really worthless given prospect for their biosimilars for Humira and Stelara with [--] competitors" [X Link](https://x.com/larrywabrams/status/1892344641137365314) 2025-02-19T22:44Z [----] followers, [---] engagements "Agree to disagree. Check out this [--] year stock chart of another biosimilar co $CHRS. I was down on them since [----]. They did a great job for a while gaining share from reference drugs but ultimately competition for #PBMs formulary positions drove down net prices after rebates. Here is $CHRS [--] year chart. IMHO $ALVO will match this 2025-2029 as its failure to gain significant market for its biosimilars for Humira Stelara Eylea become apparent" [X Link](https://x.com/larrywabrams/status/1892393636857598041) 2025-02-20T01:59Z [----] followers, [---] engagements "Turns out Denny was smart to get out of biosimilars when he did. In hindsight it was a great deal for $CHRS to sell off Cimerli for $170M to Sandoz. Recent PR by Formycon that it marketing partner Sandoz may "pause" Cimerli marketing due to extreme rebating for formulary positions causing net unit prices to plummet" [X Link](https://x.com/larrywabrams/status/1892398650757939504) 2025-02-20T02:19Z [----] followers, [---] engagements "@caseymeekMD check out this [--] day chart for another biosimilar company $FYB down 41.5% due to PR rethinking its commercialization strategy for biosimilars for Stelara (Otulfi) and Lucentis (Cimerli) and associated write-offs. Investors are terribly naive about the ability of the Big [--] PBMs to extract rebates for favored formulary positions. IMHO Biosimilar companies are not good long term investments Dr. Casey Meek MD https://twitter.com/i/web/status/1892402465565499424 https://twitter.com/i/web/status/1892402465565499424" [X Link](https://x.com/larrywabrams/status/1892402465565499424) 2025-02-20T02:34Z [----] followers, [---] engagements "why $WBA and $RAD failed now Not because of Rx margin squeeze by #PBMs but long time decline in front store convenience traffic due to online and tired merchandising. Future of [-----] sq ft drugstore model is dead. Sycamore PE has to be studying $BROS and Chick-fil-A four lane drive up model no walk-in https://twitter.com/i/web/status/1900634638911168875 https://twitter.com/i/web/status/1900634638911168875" [X Link](https://x.com/larrywabrams/status/1900634638911168875) 2025-03-14T19:46Z [----] followers, [---] engagements "My formulary auction design model reframing of $AMGN Amgen's use of bundled rebates for Repatha to exclude $REGN Regeneron's Praulent -- $CI #PBMs Express Scripts just as liable for allowing a non-standard formulary position bid basis -- where standard rebate basis is a single % off WAC 1/2 https://twitter.com/i/web/status/1923476637661921683 https://twitter.com/i/web/status/1923476637661921683" [X Link](https://x.com/larrywabrams/status/1923476637661921683) 2025-05-16T20:32Z [----] followers, [---] engagements "@costplusdrugs Mark Cuban saying his company @costplusdrugs is trying to disrupt the Big [--] #PBMs by signing a deal with grocery chain is laughable. Only way to beat the #PBMs is will be for some BCBS to offer a FFS plan at around $150 PMPY FFS and guaranteed trend of $2000 PMPY + shared risk for variations" [X Link](https://x.com/larrywabrams/status/1954319721853243731) 2025-08-09T23:11Z [----] followers, [--] engagements "@megangrA Per white paper In Google #antitrust search case .reconstructing a world but for the anticompetitive conduct of the monopolist is nearly if not totally impossible. Uh no see my "but-for" counterfactual and link to my paper below" [X Link](https://x.com/larrywabrams/status/1958649640045486142) 2025-08-21T21:57Z [----] followers, [---] engagements "@Econ_4_Everyone @ben_golub A counterfactual field experiment is needed namely test for switching over time where there is NO change in available substitutes or nature of initial substitutes. i.e how much switching is due to sheer boredom with choice" [X Link](https://x.com/larrywabrams/status/2006831673665794313) 2026-01-01T20:55Z [----] followers, [---] engagements "@manthanguptaa One implication seem to be that the architecture for Agentic memory will be fundamentally different than the Transformer neural network for LLMs. If separate any thoughts on how the two will be connected Will I be able to transfer my own long term memory to another LLM" [X Link](https://x.com/larrywabrams/status/2007954677112119547) 2026-01-04T23:17Z [----] followers, [--] engagements "@manthanguptaa Interoperability between personal Agentic memory and LLMs has major implications for competitive landscape. Why would a startup develop an Agentic memory separate from an LLM if there were no way to connect in an efficient safe manner" [X Link](https://x.com/larrywabrams/status/2007955964461539409) 2026-01-04T23:23Z [----] followers, [--] engagements "Legacy systems of record are threatened by startups who can tap in via API and build AI agents who develop decision traces which become the new system of record for decision making. E.g. Manus tapping into Slack" [X Link](https://x.com/larrywabrams/status/2008959442742886595) 2026-01-07T17:50Z [----] followers, [---] engagements "2026 Prediction - the Enterprise job title AI Prompt Engineer will be superseded by AI Context File Engineering as now Cursor stores context as files. The agent loads details only when it needs them just like a developer opens a file only when required. #AI @cursor_ai" [X Link](https://x.com/larrywabrams/status/2008971840245674127) 2026-01-07T18:39Z [----] followers, [--] engagements "@FoundationCap got it right. The road to full autonomous Agentic AI will be for startups to access Enterprise decision making (ala #Palantir) and post-train LLMs to build decision traces which then becomes the brains for point solutions to tasks. $Meta buying Manus for $2 Billion just the beginning. There will be scores of this acquisitions in [----]. https://twitter.com/i/web/status/2008979492262334889 https://twitter.com/i/web/status/2008979492262334889" [X Link](https://x.com/larrywabrams/status/2008979492262334889) 2026-01-07T19:10Z [----] followers, [--] engagements "The race to the bottom: $Hims will be threatened by AI first startups licensed by states to fill lifestyle and weight loss Rx" [X Link](https://x.com/larrywabrams/status/2008984107125231736) 2026-01-07T19:28Z [----] followers, [---] engagements "@ashpreetbedi Only problem is that legacy systems of record (SORs) will realize what you are doing is a big threat as your build up of decision traces plus new prompt window becomes the new UX . Will start blocking API access to SORs. #antitrust" [X Link](https://x.com/larrywabrams/status/2008998983365169488) 2026-01-07T20:27Z [----] followers, [---] engagements "Wonder how receptive $PLTR and Enterprise SaaS companies like $ORCL and $CRM will be to startups offering point solution Agentic AI" [X Link](https://x.com/larrywabrams/status/2009127816491872532) 2026-01-08T04:59Z [----] followers, [---] engagements "Another [----] #AI prediction involving the Big [--] #PBMs $CVS $UNH $CI versus the Big [--] Drug Distributors $COR $CAH $MCK" [X Link](https://x.com/larrywabrams/status/2013005370021589209) 2026-01-18T21:47Z [----] followers, [---] engagements "Opportunity for #AI #Startups : Big [--] #PBMs haven't rolled out yet automatic Rx adherence feedback connecting Rx prescribed with fills -- then emails to Drs and patients when adherence lags -- Why not more Rx = more $$ to PBMs. Good for employers too as Rx adherence saves treatment costs🫤 https://twitter.com/i/web/status/2014821264926589341 https://twitter.com/i/web/status/2014821264926589341" [X Link](https://x.com/larrywabrams/status/2014821264926589341) 2026-01-23T22:03Z [----] followers, [---] engagements "The sh*t is about to hit the fan for CMS @RobertKennedyJr @DrOz as the new Maximum Fair Price (MFP) reimbursement system for [--] drugs between Pharma and retail pharmacies has not be fully implemented. See December [----] letter full link 🔽 #drugpricing #PBMs" [X Link](https://x.com/larrywabrams/status/2015602043311071728) 2026-01-26T01:45Z [----] followers, [---] engagements "Letter by Senators to @RobertKennedyJr @DrOz on new Part D Maximum Fair Price reimbursement plan snafu https://www.lankford.senate.gov/wp-content/uploads/2025/12/2025-12-11-Senate-MFP-Effectuation-Letter-to-CMS-HHS.pdf https://www.lankford.senate.gov/wp-content/uploads/2025/12/2025-12-11-Senate-MFP-Effectuation-Letter-to-CMS-HHS.pdf" [X Link](https://x.com/larrywabrams/status/2015602388405735481) 2026-01-26T01:47Z [----] followers, [--] engagements "@SanCompounding Announced 8:01 AM . $MRVL stock spike 8:00 AM" [X Link](https://x.com/larrywabrams/status/2015853320863416643) 2026-01-26T18:24Z [----] followers, [---] engagements "@bobkolker liked your piece on MZ and Gabriel Leydon -- here is a recent blog post I did on them -- http://t.co/QFuT7ZpEJO http://glomoinvesting.com/machine-zone-the-4-billion-unicorn-that-walks-the-walk/ http://glomoinvesting.com/machine-zone-the-4-billion-unicorn-that-walks-the-walk/" [X Link](https://x.com/larrywabrams/status/581527030581334016) 2015-03-27T18:43Z [----] followers, [--] engagements "#PBMs formularies are a "Google" away. In a week $CVS and $ESRX will release their 2019s. I like to speculate about what formulary choices imply about the rebate game. Must see game this year will be basal insulins. Go @LillyPad .compete on list price for once with Basaglar" [X Link](https://x.com/larrywabrams/status/1022651603914899458) 2018-07-27T01:15Z [----] followers, [--] engagements "Note to Pharma: if you are a late entrant to a therapeutic class you will not get coverage by playing the PBM rebate game. Must target niches with low list = lowest net = no rebate. $Abbv doing it with #Mavyret. Set to end #HepC among Vets. Free testing. Prisoners next" [X Link](https://x.com/larrywabrams/status/1025848585491951616) 2018-08-04T20:58Z [----] followers, [--] engagements "1/ What did CEO of $MRK Ken Frazier mean by the possibility of a disintermediation in the pharmaceutical industry that can make drugs more affordable My take: $MRK goes to high list but no rebates to #PBMs get excluded initially by #PBMs on national formulary Then" [X Link](https://x.com/larrywabrams/status/1048036675132125185) 2018-10-05T02:26Z [----] followers, [--] engagements "$RAD $1 share will be delisted in [--] days. Only options : reverse split or sell #PBM unit #EnvisionRx In death spiral now" [X Link](https://x.com/larrywabrams/status/1075438952125886464) 2018-12-19T17:13Z [----] followers, [--] engagements "@tonysheng A NextGen MMO game will have a p2p trading platform based on pub-sub protocol. People will be able to stake sides in upcoming battle with winner take all sweepstake. Cash in for crypto game tokens. To avoid anti-gambling laws no cash out but can donate tokens to charity" [X Link](https://x.com/larrywabrams/status/1083047571650535424) 2019-01-09T17:07Z [----] followers, [--] engagements "Agree that drug supply chain IS in turmoil but relatively speaking its not #PBMs but retail drugstores fill margins squeezed by #PBMs and $AMZN killing front store traffic. $RAD is zombie $WBA worst Q financials since [----]. $CVS desperate to reposition front store" [X Link](https://x.com/larrywabrams/status/1114931018081894401) 2019-04-07T16:40Z [----] followers, [--] engagements "Ive been hoping for years for healthcare startups like @OscarHealth or existing companies like $AMZN or to disrupt #PBMs. It looks like $MCK and $ABC are going to roll out claims processing alt to #PBMs that startups can plug into. Heck they may even have plans to become #PBMs" [X Link](https://x.com/larrywabrams/status/1119116307167793154) 2019-04-19T05:51Z [----] followers, [--] engagements "End of an era: 2002-19 RIP my ability to analyze #PBMs $ESRX 10-K P&L now that its financials are conveniently scattered throughout $CI financials. Here is my last effort to convert FY2017 opaque gross profits to FFS equivalent plus estimate of equivalent medical loss ratio" [X Link](https://x.com/larrywabrams/status/1124140232079695874) 2019-05-03T02:34Z [----] followers, [--] engagements "$Teva stock price goes up from 63% $37 trough 12-2012 to $64 peak 6-2015 to corroborate #drugprices fixing allegations . But similar stock rise for $WBA at 98% - $41 to $81. Likely collusion by oligopsony buy-side double Big 3s (drugstores & #PBMs) to divvy up rents" [X Link](https://x.com/larrywabrams/status/1127797444329107457) 2019-05-13T04:47Z [----] followers, [--] engagements "$AMZN time to buy $RAD stop trying to get BCBSs or #PBMs to add PillPack to networks as @Prime_PBM LT contract with $WBA $ANTM LT contract with $CVS. Buy $RAD then pay off $3.5B debt. Get EnvisionRx PBM get bricks and mortar pharmacy convert front stores to Prime Clubs" [X Link](https://x.com/larrywabrams/status/1142931137624330242) 2019-06-23T23:03Z [----] followers, [--] engagements "Example of #oligopoly $FMS $DVA outsider following the rents and disrupting $CVS going into home #dialysis and fast turn around of lab testing $DGX $LH with state of the art online access by patients. https://www.bloomberg.com/news/articles/2019-07-17/cvs-pushing-into-kidney-dialysis-with-help-from-segway-inventor https://www.bloomberg.com/news/articles/2019-07-17/cvs-pushing-into-kidney-dialysis-with-help-from-segway-inventor" [X Link](https://x.com/larrywabrams/status/1151502771444518912) 2019-07-17T14:43Z [----] followers, [--] engagements "Hopefully #3 and #4 who are outside of tight tri-opoly of $NVO $LLY $SNY will compete on list although completely disappointed with lack of list and net competition by $MYL with it biosimilar Fulphila. Currently there are just a handful of insulin biosims including the Lilly Lantus knockoff branded Basaglar and the Sanofi Humlog knockoff branded Admelog. A few are pending from Mylan/Biocon and others fr Novartis-Sandoz/Gan&Lee. But even with these there will be less than [--]. Currently there are just a handful of insulin biosims including the Lilly Lantus knockoff branded Basaglar and the" [X Link](https://x.com/larrywabrams/status/1153028390351331328) 2019-07-21T19:46Z [----] followers, [--] engagements "$RAD should snap up Freds Rx accounts but not store leases" [X Link](https://x.com/larrywabrams/status/1171123299876630530) 2019-09-09T18:08Z [----] followers, [--] engagements "Employees mgt at @hashgraph #Hedera have to be totally demoralized today as $10M In SAFT options purchased a year ago between $.096 and $.12 now underwater as HBAR trading opened on 9-16-19 at $.30.but today price is around at $.04" [X Link](https://x.com/larrywabrams/status/1180640608475463680) 2019-10-06T00:27Z [----] followers, [--] engagements "#Hedera @hashgraph price discovery NOT over. Opened at $.36.now at $.04. SAFT a year ago $100M raised between $.096 and $.12 with valuation of 50B max HBAR limit at $6B. IMHO value today is basically money left in bank of approx $80M / 50B Max HBAR = $.016 CRASH" [X Link](https://x.com/larrywabrams/status/1180662654743875584) 2019-10-06T01:54Z [----] followers, [--] engagements "$TBBK (The Bancorp) #fintech #mobilebanking customer Chime still having significant processing problems. Time for the @FDICgov to start an investigation. Also alert to investors in $TBBK: GET OUT" [X Link](https://x.com/larrywabrams/status/1187503626639462400) 2019-10-24T22:58Z [----] followers, [--] engagements "Nice description by payroll processor @GustoHQ of how their ACH processing bank has a series of "sanity checks" to make sure accounts used "makes sense" Evidently both Cachet and $TBBK (The Bancorp) lacked "sanity checks" that would have detected the MyPayrollHR fraud" [X Link](https://x.com/larrywabrams/status/1188600329174044672) 2019-10-27T23:36Z [----] followers, [--] engagements "Nice description by payroll processor @GustoHQ of how their #ACH processing bank has a series of "sanity checks" to make sure accounts used "makes sense" Evidently both @CachetFS and $TBBK (The Bancorp) lacked "sanity checks" that would have detected @MyPayrollHR fraud" [X Link](https://x.com/larrywabrams/status/1193959462437937154) 2019-11-11T18:31Z [----] followers, [--] engagements "$BYD $LVS $WYNN $MGM. Looks like NV will open up Vegas way before CA Governor opens up SoCal. CA will need police to block I-15 from LA folks driving to Vegas for the weekend. Vegas will be major source of re-infection for CA if no NV - CA wall https://sfist.com/2020/04/14/newsom-lays-it-down-that-stay-at-home-orders-not-getting-lifted-anytime-soon/ https://sfist.com/2020/04/14/newsom-lays-it-down-that-stay-at-home-orders-not-getting-lifted-anytime-soon/" [X Link](https://x.com/larrywabrams/status/1250260943650443265) 2020-04-15T03:13Z [----] followers, [--] engagements "Easy to overestimate potential TIGIT sales from biotechs like $MREO $AGEN $SURF $CGEN given big players also have TIGIT trials $BMY $RHHBY and Merck KGaA. IMHO key isn't TIGIT itself but the combo /trio it is paired with. My bet $CGEN see listing https://clinicaltrials.gov/ct2/resultsterm=TIGIT&cntry=US&draw=2&rank=2#rowId1 https://clinicaltrials.gov/ct2/resultsterm=TIGIT&cntry=US&draw=2&rank=2#rowId1" [X Link](https://x.com/larrywabrams/status/1281732676760682496) 2020-07-10T23:30Z [----] followers, [--] engagements "$TRIL Jan closed call with statement that ASH gave TRIL ok to break embargo and release update to coincide with $PFE equity investment. Also there would be a further update now at ASH" [X Link](https://x.com/larrywabrams/status/1303458601852231684) 2020-09-08T22:22Z [----] followers, [--] engagements "IF #California Governor @GavinNewsom were serious about travel restrictions he would have @CHPsouthern stop weekend travel between #LA and #vegas along the I-5 $MGM $WYNN $BYD" [X Link](https://x.com/larrywabrams/status/1327453024562790400) 2020-11-14T03:27Z [----] followers, [--] engagements "$RBLX See my article on Roblox from THREE years ago https://www.google.com/amp/s/glomoinvesting.com/roblox/ https://www.google.com/amp/s/glomoinvesting.com/roblox/" [X Link](https://x.com/larrywabrams/status/1331984265282666498) 2020-11-26T15:32Z [----] followers, [--] engagements "$IBKR stock up likely based on company reporting daily average revenue trade (DARTs) of $3295 up 223% YoY and 43% MoM. But IMHO market should also pay attention to report of client margin balance at $40.8 Billion up 49% YoY. Without expert risk management this is alarming" [X Link](https://x.com/larrywabrams/status/1356326640830148608) 2021-02-01T19:40Z [----] followers, [--] engagements "$FTAC Payoneer #SPACs PR keep saying it's Betsy Cohen's SPAC. She is really a front for her son Daniel G. Cohen this generation's Enron "smartest guy in the room" See my paper on their $TBBK accounting https://medium.com/@larrywabrams/the-bancorp-a-test-for-post-enron-gaap-5b4881bd23bd https://medium.com/@larrywabrams/the-bancorp-a-test-for-post-enron-gaap-5b4881bd23bd" [X Link](https://x.com/larrywabrams/status/1357773568809947138) 2021-02-05T19:30Z [----] followers, [--] engagements "$EVGN a [--] division mini Ginkgo Bioworks at 1% of the $20 Billion valuation SPAC $SRNGU reported has placed on Ginkgo. $EVGN s computational biology platform has produced synthetic bacteria in area of seed coating herbicides and Microbiome to boost oncology cell therapies" [X Link](https://x.com/larrywabrams/status/1381074114211799041) 2021-04-11T02:38Z [----] followers, [--] engagements "$EVGN strength is a DISCOVERY platform and MIXING of microbes and bacteria in area of seed coating and gut Microbiome. Ginkgo Bioworks strength is sophisticated stitching together of microbes and bacteria relying on others for discovery. I like $EVGN at 1% valuation of $SRNGU" [X Link](https://x.com/larrywabrams/status/1381375852915527682) 2021-04-11T22:37Z [----] followers, [--] engagements "$RHBBY "Sales in the Pharma Div decreased 9% to CHF [----] B mainly because of the continued biosimilars competition." I was [--] 1/2 years ahead in predicting meaningful #biosimilars competition. No need for statist policies advocated by @peterbachmd https://nu-retail.com/biosimilar-entry/ https://nu-retail.com/biosimilar-entry/" [X Link](https://x.com/larrywabrams/status/1384986998990012422) 2021-04-21T21:46Z [----] followers, [--] engagements "$AMZN Pharmacy -- do not sell short its potential to disrupt #PBMs and bricks and mortar $CVS $WBA $RAD with a business model featuring loss leader SIX Month supply of generics for $1 a month offset by high margins on private label vitamins and beauty products" [X Link](https://x.com/larrywabrams/status/1407894905859436544) 2021-06-24T02:54Z [----] followers, [--] engagements "Just test out $UNH new integrated Optum Store -- cheap Rx generics in-home testing kits teladoc. Has a slick UX. OTH $CI Express Scripts and $CVS online has a tired look offering only Rx. Lots of catching up to https://store.optum.com/ https://store.optum.com/" [X Link](https://x.com/larrywabrams/status/1416857017310801920) 2021-07-18T20:26Z [----] followers, [--] engagements "$JNJ vs $PFE settle #antitrust lawsuit out of court re: lump sum rebate use in #PBMs formulary placement of reference vs #biosimilars. IMHO big win for competition vs competitors. #ChicagoSchool See my paper https://nu-retail.com/antitrust-biosimilars/ https://nu-retail.com/antitrust-biosimilars/" [X Link](https://x.com/larrywabrams/status/1419672907752427520) 2021-07-26T14:56Z [----] followers, [--] engagements "$CVS is closing [---] stores. I predicted in [----] that $WMT $4 cash / Rx would be the beginning of the end of the drugstore business model of the pharmacy subsidizing the front store http://www.nu-retail.com/CVS_Caremark_Merger.pdf http://www.nu-retail.com/CVS_Caremark_Merger.pdf" [X Link](https://x.com/larrywabrams/status/1461790054515449873) 2021-11-19T20:14Z [----] followers, [--] engagements "Table stakes for online pharmacies will soon become integrated Tele-Dr / Rx dispensing/ online delivery like new offering by $GDRX Take note: @costplusdrugs $HIMS @OptumRx and a host of startups" [X Link](https://x.com/larrywabrams/status/1483572654913179651) 2022-01-18T22:50Z [----] followers, [--] engagements "$ICL Wall Street Journal article today on how Brazil seeking alternative sources of Potash from Canada now that sources from Russia and Belarus cut off. IMHO there is a mad rush now in Europe and India to sign potash contracts with $ICL out of Dead Sea IZ" [X Link](https://x.com/larrywabrams/status/1508913886652555264) 2022-03-29T21:07Z [----] followers, [--] engagements "$RAD stock crash another sign that retail drugstore profitability -- chains and independents both -- are under stress by online both of Rx and front store stuff -- Politicians need to realize that eliminating #PBMs spread pricing will not save retail drugstores" [X Link](https://x.com/larrywabrams/status/1512179173091016704) 2022-04-07T21:23Z [----] followers, [--] engagements "@Biotech2k1 Every decade in #Biotech there is a breakthrough technology that will enable a startup to "go the distance" (i.e. not be bought out) and become a 50x-100x. $AMGN and mAB in the early 00s was one -- iPSC NK ( $FATE $SANA and others ) could be the one to "go the distance" in 20s" [X Link](https://x.com/larrywabrams/status/1520247469749129216) 2022-04-30T03:43Z [----] followers, [--] engagements "$KSS Kohl's buyout offer suggests $RAD Rite-Aid could next with parts -- real estate and Rx customer accounts -- worth more than current Enterprise Value (EV) of about $3.5B (MC + debt). Retail drugstore as convenience concept is dead with $RAD is the sickest $CVS $WBA" [X Link](https://x.com/larrywabrams/status/1534234995274833920) 2022-06-07T18:05Z [----] followers, [--] engagements "@B_Madden4 @navituspbm @PrescryptiveH Really $AMZN wants One Meds software more than bricks and mortar. Ultimate goal is alternative end-to-end software platform to EHR Epic and Cerner eRx Surescripts and #PBMs POS formulary software. 1/2" [X Link](https://x.com/larrywabrams/status/1550352307757338625) 2022-07-22T05:29Z [----] followers, [--] engagements "@B_Madden4 @navituspbm @PrescryptiveH $AMZN disruption via $OMED acquisition to Big [--] #PBMs will be (1) move formulary management to POC from POS (2) narrow network pharmacy benefit where narrow is One Med Drs reducing PMPY drug spend 20% to $850" [X Link](https://x.com/larrywabrams/status/1550353247583420417) 2022-07-22T05:33Z [----] followers, [--] engagements "$DNA Ginkgo collaboration with Bayer in ag synthetic bio puts pressure on $CTVA to seal collab / investment in Lavie Bio subsidiary of $EVGN" [X Link](https://x.com/larrywabrams/status/1551674026077999104) 2022-07-25T21:01Z [----] followers, [--] engagements "$UNH OptumRx #PBMs Optum Store (slick UX with @truepill_rx API) - just got email touting all the OTC therapeutics they offer - they make more gross profits on OTC than generic Rx hurt traffic at retail pharmacies. $CVS Caremark would never do this" [X Link](https://x.com/larrywabrams/status/1583120048847486976) 2022-10-20T15:36Z [----] followers, [--] engagements "$UNH $AMZN understand this but startup online Rx fill and delivery cos like @costplusdrugs @GoodRx $GDRX $HIMS do not Margins are NOT in generic Rx but cross selling healthcare products and vitamins. See this Optum Store Twitter ad" [X Link](https://x.com/larrywabrams/status/1619011403888877569) 2023-01-27T16:36Z [----] followers, [---] engagements "Good idea.but.while Netflix-like fixed $ / year subscription will lowers average cost of Hep C treatment the more the useage important NOT to include generous inflation protection clause and obtain sealed bids by more than two companies $ABBV and $GILD Rewarding to see our Netflix model with @BillCassidy on Hep C headed to nationwide program. Orig description here: https://t.co/YXz8LLMdE3 https://t.co/5g3Nosu7Wq Rewarding to see our Netflix model with @BillCassidy on Hep C headed to nationwide program. Orig description here: https://t.co/YXz8LLMdE3 https://t.co/5g3Nosu7Wq" [X Link](https://x.com/larrywabrams/status/1633585594642370560) 2023-03-08T21:48Z [----] followers, [---] engagements "$CI #PBM Evernorth (aka Express Scripts) caving to critics by offering a FFS biz model with fixed $ copays no spread pricing 100% pass thru of rebates. Big Q is will they reveal FFS PMPY and target drug spend as PMPY Bet they wont reveal either - still not transparent" [X Link](https://x.com/larrywabrams/status/1651308697573031936) 2023-04-26T19:34Z [----] followers, [---] engagements "$CI #PBM to offer new plan featuring fixed $ copay. $5 for generics $25 for preferred brand and $45 for preferred specialty injectable. If other big #PBMs follow people with insurance who had been paying cash at @costplusdrugs and $GDRX will return to Big [--] plans" [X Link](https://x.com/larrywabrams/status/1651310659978797058) 2023-04-26T19:41Z [----] followers, [---] engagements "$GDRX and @costplusdrugs are doomed now that $CI #PBMs Express Scrips has caved to critics to offer now fixed $ copays. People with insurance will no longer find cash Rx prices lower than fixed $ copays that one of the Big [--] will offer. The other [--] will be pressured to match" [X Link](https://x.com/larrywabrams/status/1651313933230419970) 2023-04-26T19:54Z [----] followers, [---] engagements "@varma_ashwin97 Contracting externality is for forcing #PBMs to apply bundled rebates for formulary position- $AMGN raising rivals $HZN fixed cost via tariff (rebate) to gain access to formulary position. See my paper on market design https://papers.ssrn.com/sol3/papers.cfmabstract_id=4387935 https://papers.ssrn.com/sol3/papers.cfmabstract_id=4387935" [X Link](https://x.com/larrywabrams/status/1658577971685527557) 2023-05-16T20:59Z [----] followers, [---] engagements "@FTC right to target $AMGN -- leader in using bundled rebates to raise rivals costs creating negative margins. See [----] lawsuit by $RGEN where $AMGN bumped up rebates for Otelza and Enbrel if #PBMs chose Repatha and excluded $RGEN Praluent. See case" [X Link](https://x.com/larrywabrams/status/1658601745973678080) 2023-05-16T22:34Z [----] followers, [---] engagements "@DaytonPubPolicy Wfh Bay Area also moving out of Santa Cruz and Aptos as it also has Bay Area home prices" [X Link](https://x.com/larrywabrams/status/1658671904184766464) 2023-05-17T03:12Z [----] followers, [--] engagements "@Kevin_M_Biotech @BertrandBio Yes $AMGN reported 1Q23 sales of Enbrel down 33% because of price competition from therapeutic similar #biosimilars of Humira including their own" [X Link](https://x.com/larrywabrams/status/1664310703870861312) 2023-06-01T16:39Z [----] followers, [--] engagements "@AnotherBio You are not alone. A bunch of retail $CHRS investors see the same thing. OTH $1 B revenue in [----] not sure thing. 50% chance $ABBV files breach of contract Tori get a CRL Cimerli 2Q23 revenue disappoints or CEO Lanfear stuffs channels again like he did with Udencya in 2019" [X Link](https://x.com/larrywabrams/status/1673190501707829248) 2023-06-26T04:56Z [----] followers, [---] engagements "In just [--] days since acquisition of $SURF at $5.28 /share $CHRS stock has declined 28% to $3.80. Watch the number of class action lawsuits claiming breach of fiduciary duty on part of SURF management multiply. This deal will never close unless $CHRS kicks in $18+M in shares" [X Link](https://x.com/larrywabrams/status/1673394740379914243) 2023-06-27T18:16Z [----] followers, [----] engagements "@DesatCap $WBA written about in Jim Collins book Good to Great in [----]. I felt they should have followed $CVS in 2010s and bought a #PBM . No they had a hedgehog strategy well look at the slow poke now- back to [----] low 🦔🦔🦔" [X Link](https://x.com/larrywabrams/status/1673781010289553408) 2023-06-27T19:51Z [----] followers, [--] engagements "@qniatof @chaperonycon Sales data compiled by Symphony is based on WAC or gross prices not net after rebates. $26 M reported for Cimerli in June is gross sales. Net is likely 1/2 or $13 M . $CHRS projects $48-$52M NET for 2Q. Will just hit that with $26M net for Udenyca and $25M net for Cimerli" [X Link](https://x.com/larrywabrams/status/1678674429898031104) 2023-07-11T07:59Z [----] followers, [---] engagements "@qniatof @chaperonycon Ha ha only two people awake at this time is me on the West Coast USA at [--] AM and you Chris in Sweden at [--] AM" [X Link](https://x.com/larrywabrams/status/1678675653670080513) 2023-07-11T08:04Z [----] followers, [---] engagements "Blue Shield of CA dropping $CVS as #PBMs is definitely an attack on vertically integrated PBMs - cobbling together mail order from @costplusdrugs and $AMZN but still retaining suspect vendor for formulary and rebate Mgt Prime Therapeutics who outsources to Express Scripts" [X Link](https://x.com/larrywabrams/status/1692240851085435251) 2023-08-17T18:23Z [----] followers, [---] engagements "$CVS $WBA today at all time lows. Not surprising. Front store was never very profitable Retail was due to generic margins holdup by #PBMs until $WMT started $4/Rx cash in [----]. Now even owned mail order not very profitable due to $AMZN & $GDRX competition (and PBM coverage)" [X Link](https://x.com/larrywabrams/status/1692264492720349668) 2023-08-17T19:57Z [----] followers, [---] engagements "$CVS $WBA today at new lows. Not surprising. I predicted in [----] that $WMT $4/Rx cash would be start of an assault on the profitability of the drugstore business model eventually (longer than I thought) leading to drug stores following dime stores as retail dinosaurs" [X Link](https://x.com/larrywabrams/status/1692265771144208869) 2023-08-17T20:02Z [----] followers, [----] engagements "My [----] paper predicting the effect of the $WMT $4/Rx on the Big [--] drugstore / #PBMs tacit collusion to hold up generic prices and the end of the drugstore business model of the back pharmacy subsidizing the front store $CVS $WBA" [X Link](https://x.com/larrywabrams/status/1692267647247712587) 2023-08-17T20:10Z [----] followers, [---] engagements "Blue Shield CA CEO says in WSJ article that its cobbled together #PBMs replacement for $CVS Caremark includes Rx claims process Abarca. Who is Abarca A small "healthcare administrator" (Facebook page quote) out of Puerto Rico. This move has all the markings of a disaster" [X Link](https://x.com/larrywabrams/status/1692274219567251631) 2023-08-17T20:36Z [----] followers, [---] engagements "$CVS getting into co-producing and marketing a low list private label biosimilar of Humira called Hyrimoz from Sandoz. Key to understanding strategy is knowing that Hyrimoz is only [--] of [--] interchangeable among [--] biosimilars for Humira 1/n" [X Link](https://x.com/larrywabrams/status/1694880472734851423) 2023-08-25T01:12Z [----] followers, [----] engagements "No surprise -- CVS's main customer for private label Hyrimoz will be CVS retail drugstores whose pharmacists will exclusively "interchange" Hyrimoz for Humira Rx in states with laws that allow "interchangeables" without prior approval of prescribing Dr. 2/n" [X Link](https://x.com/larrywabrams/status/1694881364955508871) 2023-08-25T01:16Z [----] followers, [---] engagements "This $CVS move to getting into the biosimilar INTERCHANGEABLE manufacturing and marketing business suggest that they see greater profit from biosimilar retail markups than retained formulary rebates from off-patent blockbusters biologic incumbents like Humira 3/3" [X Link](https://x.com/larrywabrams/status/1694883095915483396) 2023-08-25T01:23Z [----] followers, [---] engagements "Note to @linakhanFTC :The motive for first mover vertical integration in drug supply chain is often to disrupt tacit collusions elsewhere to hold up margins: (1) CVS retail + Caremark #PBMs - created preferred provider networks breaking prior hold up of retail generic margins 4/n" [X Link](https://x.com/larrywabrams/status/1694885297035866419) 2023-08-25T01:31Z [----] followers, [---] engagements "@linakhanFTC Note to @linakhanFTC : $CVS Health vertical integration with Sandoz to co-manufacturer and market of interchangeable biosimilars signals effort to move away from retained rebates dependent biz model to specialty drug retail margins biz model 5/5" [X Link](https://x.com/larrywabrams/status/1694886358823952447) 2023-08-25T01:36Z [----] followers, [---] engagements "@Pharmdca $RAD value is in patient records that bankruptcy court can sell to $CVS and $WBA. Was a time years ago it could have sold leases but not now" [X Link](https://x.com/larrywabrams/status/1695112809942761973) 2023-08-25T16:36Z [----] followers, [---] engagements "@Pharmdca My [----] SeekingAlpha calculations suggesting at time $RAD worth more closed than open due to value of patient accounts to $CVS and $WBA" [X Link](https://x.com/larrywabrams/status/1695113958204801488) 2023-08-25T16:40Z [----] followers, [---] engagements "@StanMehr @CVSHealth @Sandoz_Global IMHO this moves is a signal that $CVS sees more future profits from on-invoice mfg to dispenser markups and #PBM to payer spreads on #biosimilars than off-invoice PBM retained rebates. Key here is CVS is backing an INTERCHANGEABLE biosimilar. 1/2" [X Link](https://x.com/larrywabrams/status/1696181983221805285) 2023-08-28T15:24Z [----] followers, [---] engagements "@StanMehr @CVSHealth @Sandoz_Global By co-mfg an interchangeable biosimilar $CVS is capitalizing on its power to switch Humira Rx to its own product at POS without Dr prior approval earning double margin (1) mfg markup (2) PBM spread" [X Link](https://x.com/larrywabrams/status/1696183496350535747) 2023-08-28T15:30Z [----] followers, [---] engagements "@StanMehr @CVSHealth @Sandoz_Global $CVS getting into the co-mfg of an INTERCHANGEABLE #biosimilar represents the final step in an complete vertical integration of Rx - owned mfg to owned specialty distributor to owned retail managed by owned #PBM as agent for owned insurance company" [X Link](https://x.com/larrywabrams/status/1696189132891144624) 2023-08-28T15:52Z [----] followers, [--] engagements "@StanMehr @CVSHealth @Sandoz_Global Ha ha $CVS by owning all levels of Rx - mfg distribution dispensing PBM insurance- is able to shift profit center to another level if government steps up regulation of any one" [X Link](https://x.com/larrywabrams/status/1696190443917390007) 2023-08-28T15:58Z [----] followers, [--] engagements "@StanMehr Sad that Medicare Part D has autoimmune drugs as a protected class preventing switching of Humira and it biosimilars for Enbrel in certain indications. $CVS in his commercial formulary has Humira AND Enbrel covered in [--] of [--] indications" [X Link](https://x.com/larrywabrams/status/1696567117741531375) 2023-08-29T16:54Z [----] followers, [--] engagements "@rachelcohrs Sad that Medicare Part D has autoimmune drugs as a protected class preventing switching of Humira and it biosimilars for Enbrel in certain indications. $CVS in his commercial formulary has Humira AND Enbrel covered in [--] of [--] indications" [X Link](https://x.com/larrywabrams/status/1696567929486143736) 2023-08-29T16:58Z [----] followers, [--] engagements "@D1Fund @SteveWagsInvest $CHRS Dont expect much Yusimry (Humira #biosimilar sales from @costplusdrugs much hype not enough customer adoption no scale running out of funds Cuban no deep pockets use API software from @truepill_rx which has had [--] layoffs cuz other online Rx co also losing money" [X Link](https://x.com/larrywabrams/status/1697350993254777304) 2023-08-31T20:49Z [----] followers, [----] engagements "@qniatof @D1Fund @SteveWagsInvest @costplusdrugs @truepill_rx All new online Rx GoodRx Cuban struggling with profitability. Humira market $21B in [----] but maybe $10B in [----] due to price drops so $CHRS 4% sound great at $400M relative to today butprofit positive cash flow On road to [----] minimum revenue goal of $1.2B No" [X Link](https://x.com/larrywabrams/status/1697643671808848103) 2023-09-01T16:12Z [----] followers, [--] engagements "@qniatof @D1Fund @SteveWagsInvest @costplusdrugs @truepill_rx $CHRS facing fast dropping Humira price market. $21B in [----] maybe $10B in [----] so 4% share= $400 M is great but by [----] Humira market likely $4B so 8% share is $320M in short $CHRS will NOT reach its [----] minimum revenue goal of $1.2B" [X Link](https://x.com/larrywabrams/status/1697647013582799260) 2023-09-01T16:26Z [----] followers, [---] engagements "$WBA CEO and CFO leaving suddenly $RAD planning bankruptcy. This isn't because of opioid lawsuits but death of the retail drugstore business model -- declining profits from Rx fill and increasing losses from front store due to $AMZN and online" [X Link](https://x.com/larrywabrams/status/1697760999246623028) 2023-09-01T23:58Z [----] followers, [---] engagements "@a4floridacajun Yes #PBMs unions agricultural grain storage co-ops are all middlemen by as seen by that insightful neoliberal economist in the 50s as countervailing powers to oligopolies capturing rents and passing it on to consumers in form of lower prices or higher wages. 1/n" [X Link](https://x.com/larrywabrams/status/1699282577000112611) 2023-09-06T04:45Z [----] followers, [---] engagements "@JulieChangRE @realest49919420 Tyler Childers Morgan Wallen Zach Bryan Jason Isbell Bradley Zimmerman Lainey Wilson Jelly Roll" [X Link](https://x.com/larrywabrams/status/1702126947466440728) 2023-09-14T01:07Z [----] followers, [---] engagements "@ChickenJoeSTL At least locally owned Bus Loop Burgers survived and thrives in new but uninspiring strip mall in St. Ann. Too bad not more name restaurants in StL City couldnt keep legacy going in new albeit faceless suburban locations" [X Link](https://x.com/larrywabrams/status/1702411717106606108) 2023-09-14T19:59Z [----] followers, [--] engagements "@JKGY42686232302 @qniatof No crafty CEO Lanfear planning to issue more stock in mid-Oct after sure thing pop pre announce 3Q channel stuffed Cimeri sales not chancing to wait for high risk event of FDA Tori decision . Thats why Landfear is dragging on Tori clinic inspections" [X Link](https://x.com/larrywabrams/status/1702434680841355451) 2023-09-14T21:30Z [----] followers, [--] engagements "#Econtwit #PBMs quiz: How might Akerlofs paper Market for Lemons apply to GPO-facilities formulary position market with mix of commercial and Part B patients And cause of ASP decline upon #biosimilar entry" [X Link](https://x.com/larrywabrams/status/1703462966979604574) 2023-09-17T17:36Z [----] followers, [---] engagements "Hey @john_waynez -- your tweet "hope" that $CHRS would " slow sto potentially turning positive" after bouncing off lower end of the bollinger band on the 19th has not materialized.broke thru today.🤷♂" [X Link](https://x.com/larrywabrams/status/1704941112497168835) 2023-09-21T19:30Z [----] followers, [----] engagements "@scooter88153165 No but efficacy and persistence is more complicated than simply targeting. This is screenshot from opening address of NK2023 meeting starting today in Oslo Norway. Here is a pdf of the program" [X Link](https://x.com/larrywabrams/status/1706724322717712770) 2023-09-26T17:36Z [----] followers, [---] engagements "@iskander @AaronGoodman33 EMR is the largest SaaS untapped profit market out there. There will be challenger to EPIC. Slow but steady it will be $AMZN dogfooding a new EMR system with its recent acquisition of One Medical" [X Link](https://x.com/larrywabrams/status/1707240050289958999) 2023-09-28T03:45Z [----] followers, [--] engagements "@RolfeNeelsen Based on todays $CHRS announcement of 100K dosages to date of Cimerli and 50% gross to net I have 3Q sales at $40M . Udencya also est. great net sales at $45M . Total net 3Q $85M. Short of your est $100M. Impressive but bad $XBI market and funds sour on CEO oncology strategy" [X Link](https://x.com/larrywabrams/status/1709600778615435662) 2023-10-04T16:06Z [----] followers, [---] engagements "@UCPrezDrake time to investigate UCSC Dept. of Race & Ethnic Studies and two profs Christine Hong and Jennifer Kelly sponsoring an anti-Zionist conference in #SantaCruz Registration required signing these points of unity. Too many UCSC profs spreading hate against Israel" [X Link](https://x.com/larrywabrams/status/1711915849001611290) 2023-10-11T01:25Z [----] followers, [--] engagements "CA State Senator John Laird: time to investigate UCSC and two profs Christine Hong and Jennifer Kelly sponsoring an anti-Zionist conference. Registration required signing these points of unity. Too many UCSC profs spreading hate against Israel" [X Link](https://x.com/larrywabrams/status/1711917331469963616) 2023-10-11T01:31Z [----] followers, [---] engagements "@AmherstCollege President Elliott - your silence is defining regarding Hamas terrorist acts against Israel" [X Link](https://x.com/larrywabrams/status/1711930895446454556) 2023-10-11T02:25Z [----] followers, [---] engagements "@MattBiotech We are close. We use different envelope math: me $44M 3Q net for Cimerli you $40M 3Q net. need to follow @Biohazard3737 quarterly posting of Symphony data (which only big time investors him can afford to buy) to get a more accurate estimate of gross WAC sales of $CHRS drugs" [X Link](https://x.com/larrywabrams/status/1712881791319920647) 2023-10-13T17:23Z [----] followers, [---] engagements "@andrewpannu Need to consider IP and patent extension via at home sub-Q and on-body injections of original Dr office infused drugs. One problem is this changes management from insurance Co and Part B to Big [--] #PBMs and Part D more aggressive rebate negotiations" [X Link](https://x.com/larrywabrams/status/1715043828300943862) 2023-10-19T16:34Z [----] followers, [---] engagements "@DaytonPubPolicy Better Central Cali schools put more money in competitive sports indigenous to area: surfing skateboarding rock fishing frisbee golf bike racing rock climbing" [X Link](https://x.com/larrywabrams/status/1715810699455394049) 2023-10-21T19:22Z [----] followers, [--] engagements "@JWurzak Related questions: what next West Coast towns with indie vibe benefiting from WFH and urban doom loop: my picks (1) Bellingham WA (2) Paso Robles CA (3) San Luis Obispo CA (3) Mt Vernon WA (4) Bayside / Los Osos CA. Coffeehouses in Bellingham WA filled with Microsoft WFH" [X Link](https://x.com/larrywabrams/status/1721232216263672048) 2023-11-05T18:25Z [----] followers, [---] engagements "@JWurzak @AlliedCRE Wrong. There are a number of Central Cali towns with indie vibe benefiting from WFH and urban doom loop: Paso Robles San Luis Obispo (3) Bayside / Los Osos (4) Atascadero (4) Templeton. Coolest coffeehouse in Central Cali is AMSTRDM in Paso Robles" [X Link](https://x.com/larrywabrams/status/1721239403983765991) 2023-11-05T18:53Z [----] followers, [--] engagements "Pegfilgrastim #biosimilar market now brutal after [--] years with 5+ entrants: $CHRS just reported 3Q23 market share for Udenyca 🔼 big QoQ from 12.3% to 16% yet sales 🔼 only $31.7 M to $33.0 M cuz total market Q 🔽.(why post-COVID bump in ops over) and net prices continue to 🔽" [X Link](https://x.com/larrywabrams/status/1721661531539312915) 2023-11-06T22:51Z [----] followers, [----] engagements "@ej23ny @user889889 No Big Pharma not buyout candidate for $CHRS as they now see #biosimilars market no longer as a high touch / high profit biologics market as CEO Landfear did in [----] but more as a small molecule generics race to the bottom pricing strategy of gaining market share. 1/2" [X Link](https://x.com/larrywabrams/status/1722733780425994261) 2023-11-09T21:51Z [----] followers, [---] engagements "@ej23ny @user889889 Inflection point has been the market killing doom loop pricing strategy of Sandoz with Ziextenzo - increasing market share of non-OnPro market from 6% to 22% eliminating channel marketing costs and going with doom loop ASP drop of 50% in [--] years now at 1/2 ASP of Udencya" [X Link](https://x.com/larrywabrams/status/1722737658613682507) 2023-11-09T22:07Z [----] followers, [---] engagements "No Existential moment for biosimilars market as WS no longer sees it as high touch play nice price disciplinebiologics market as CEO Landfear argued for $CHRS in [----] but a race to the bottom small molecule generics market 1/2" [X Link](https://x.com/larrywabrams/status/1722739420431040536) 2023-11-09T22:14Z [----] followers, [---] engagements "Inflection point for change in view of #biosimilars market has been the successful doom loop pricing by Sandoz for Ziextenzo - gaining Non-OnPro market share from 8% to 22% in [--] years foregoing channel marketing expenses for 50% ASP price drop now 1/2 that of $CHRS" [X Link](https://x.com/larrywabrams/status/1722741222023061924) 2023-11-09T22:21Z [----] followers, [---] engagements "Biosimilars market no longer a high touch price discipline market as Landfear argued in [----] as early entrants now subject to "doom loop" pricing pioneered by Sandoz with Ziextenzo. Will spread causing Cimerli revenue to fall after mid-2024. $CHRS [----] projections f***ed" [X Link](https://x.com/larrywabrams/status/1722812852703248687) 2023-11-10T03:06Z [----] followers, [----] engagements "Here is a pix of Sept [----] graph where $CHRS was placing $1.2B revenue projection at end of graph" [X Link](https://x.com/larrywabrams/status/1722825180983300257) 2023-11-10T03:55Z [----] followers, [---] engagements "As seen above the core belief of $CHRS that their "biosimilar cash flows support development of I-O pipeline" has been shattered by slight 3Q23 revenue miss due to Udenyca price erosion to fend off "doom loop" pricing by Sandoz. Company faces an existential crisis" [X Link](https://x.com/larrywabrams/status/1722828264786231391) 2023-11-10T04:07Z [----] followers, [---] engagements "The big [--] drugstore chains $CVS $WBA and bankrupt Rite-Aid had the chance to diversity into high end cosmetics- now while their front of stores struggle the Black Friday crowds are flocking to Sephora and Ulta" [X Link](https://x.com/larrywabrams/status/1728149800800198758) 2023-11-24T20:33Z [----] followers, [---] engagements "$CVS Caremark moving to cost + reimbursement for fill by retail pharmacies really is a signal that this source of #PBMs gross profits was small and now declining. Majority of biz model now is formulary rebates and channel sales markup on medical benefit specialty biologics" [X Link](https://x.com/larrywabrams/status/1732478135571202524) 2023-12-06T19:12Z [----] followers, [---] engagements "One less UCSC faculty member of extremist Institute for the Critical Study of Zionism at @UCSC whose members organized antisemitic rallies on campus" [X Link](https://x.com/larrywabrams/status/1733976280104865890) 2023-12-10T22:25Z [----] followers, [---] engagements "@MattBiotech Agreed $CHRS [----] revenue will be good. You at $520M me at $470M. But problems after 2Q24 as more biosimilar entrants drive net prices down. Stock price already reflects [----] revenue target of $1.2B is kaput and tepid cash flow positive not enough to fund IO pipeline" [X Link](https://x.com/larrywabrams/status/1737580601891520983) 2023-12-20T21:07Z [----] followers, [---] engagements "@stocksdd @MattBiotech What revenues they gain via Udenyca OBI in 2H24 they lose back via really intense price competition and some share loss in PFS pegfilgrastim market. Plus and a couple a new entrants to ranibizumab market will cause Cimerli revenue decline starting 2H24" [X Link](https://x.com/larrywabrams/status/1739905888734032255) 2023-12-27T07:07Z [----] followers, [---] engagements "@zohmbastic Read the fine print Zohmbastic Yes $CVS will prefer Humira biosimilars over Humira in [----] - but NOT from $CHRS but from Sandoz and Biocon" [X Link](https://x.com/larrywabrams/status/1742683435628732905) 2024-01-03T23:04Z [----] followers, [---] engagements "@guptavinay These are powerful drugs with potential serious side effects. Best prescribed in person by PCP with ongoing relation rather than online Dr working from who knows where. $LLY is asking for trouble" [X Link](https://x.com/anyuser/status/1743336308121223211) 2024-01-05T18:19Z [--] followers, [--] engagements "@StanMehr Success of #biosimilars markets should measured by net prices not WAC or market share. Better to have a single drug dominate at 80% off WAC than [--] drugs share market at 40% off. $ABBV rebating as much as $15 Billion to payers who have to use to lower premiums to keep within MLR" [X Link](https://x.com/larrywabrams/status/1745285128539312598) 2024-01-11T03:22Z [----] followers, [--] engagements "@Space_Force__ @PharmaPinkSheet Agreed $LLY LillyDirect for its own self-injectables and small molecule drugs is not a threat to #PBMs but its UX featuring direct-to-consumer delivery via @truepill API pharmacy- as-a-service is another blow to bricks & mortar pharmacies. $CVS $WBA $RAD" [X Link](https://x.com/larrywabrams/status/1747033113728012314) 2024-01-15T23:08Z [----] followers, [---] engagements "$CHRS followers need to look at [--] balance sheet items: (1) calculate days receivable = (Accounts Receivable ( 92% from Big [--] Distributors) / 3Q23 Net Revenue but add back off invoice rebates) * [--] . You will Lanfear still inflates sales by channel stuffing" [X Link](https://x.com/larrywabrams/status/1747396616238354794) 2024-01-16T23:13Z [----] followers, [---] engagements "$CHRS balance sheet item (2) look deep into latest 10-Q and see they broke inventory down by expectations for useage. Turns out they estimate 1/2 wont be used until after [----] due to way too much Yusimry purchases relative to tepid sales expectations in 2024" [X Link](https://x.com/larrywabrams/status/1747398765768798314) 2024-01-16T23:21Z [----] followers, [---] engagements "@jfais20 $CHRS No sufficient operating cash flow til maybe mid-2025 to internally finance trials with Tori and internal OI . Will require re-licensing to someone else at % and milestone payments above what they are obligated to pay Junshi See below. Net difference in % is problematic" [X Link](https://x.com/larrywabrams/status/1748394611138298138) 2024-01-19T17:18Z [----] followers, [---] engagements "@jfais20 In short $CHRS is between a rock and a hard place to finance new trials with Tori - where rock is insufficient internal cash flow til maybe after mid-2025 and hard place is re-licensing Tori at material % of net sales greater than the original 20% they have to pay Junshi" [X Link](https://x.com/larrywabrams/status/1748399123848691722) 2024-01-19T17:36Z [----] followers, [----] engagements "@StanMehr @stocksdd @MattBiotech Decision-making re: #biosimilars trials trivial compared to full [--] phase RCTs of combo oncology drug: (1) What SoC to use for control arm (1) What endpoint -PFS vs OS Also years before cash flow: $CHRS won't see cash from new USA Tori combo trial till mid-2027 to 2028" [X Link](https://x.com/larrywabrams/status/1749571335595188391) 2024-01-22T23:14Z [----] followers, [---] engagements "@stocksdd @StanMehr @MattBiotech Key to achieving your total $CHRS pegfilgrastim revenue of $250M in [----] is what share it can get in OBI segment. I have them needing 25% share to get your number. Is that doable Yes with 20% rebate off WAC and $AMGN slow to follow. It all depends on how slow $AMGN responds" [X Link](https://x.com/larrywabrams/status/1749660456946647094) 2024-01-23T05:08Z [----] followers, [---] engagements "@stocksdd @StanMehr @MattBiotech Per CMS: there are / will be no separate J-Codes and ASPs for OBIs vs prefilled. There is only one drug J-Code for both - J2506 - but [--] separate codes for Dr admin - CPT code [-----] for prefilled and CPT code [-----] for OBI. Not good for $CHRS" [X Link](https://x.com/larrywabrams/status/1749958067364749675) 2024-01-24T00:51Z [----] followers, [---] engagements "@stocksdd @StanMehr @MattBiotech From CMS here is a screenshot of coding -- [--] codes for Dr admin -- prefilled vs OBI - and only [--] code option for drug. Not good for $CHRS as OBI market not insulated from price competition in the prefilled market" [X Link](https://x.com/larrywabrams/status/1749959797452214425) 2024-01-24T00:58Z [----] followers, [---] engagements "While the #biosimilars market began in [----] it wasn't until [----] that price competition started to take off What changed Yes to Govt policy and # of entrants. IMHO another factor has been divestiture by "white shoe" old-line $NVS $PFE $MRK to cos with a generics mind-set" [X Link](https://x.com/larrywabrams/status/1752170153541071049) 2024-01-30T03:21Z [----] followers, [---] engagements "Starting to see the wisdom of $CHRS CEO Landfear in selling off Cimerli as "non-core" Why Back in 2020-21 he saw that old-line "white shoes" Pharma $MRK $NVS $PFE were selling off their #biosimilars to cos with a generics price competition mindset" [X Link](https://x.com/larrywabrams/status/1752173050710335749) 2024-01-30T03:33Z [----] followers, [----] engagements "With the disappointing launch of $AMGN Humira biosimilar and the delayed launch of its Eylea biosimilar and seeing other old-line Pharma $MRK $PFE $NVS divest their #biosimilars lines to co with generics price competition mindset I expect $AMGN to divest also within a year" [X Link](https://x.com/larrywabrams/status/1752178490936615272) 2024-01-30T03:54Z [----] followers, [---] engagements "The Big [--] #PBMs [----] formulary for Humira and its #biosimilars is indicative that choice is based on the product of net unit price * expected demand (where brand and marketing clout matters) not just net price. This is why small co $ALVO $OGN $CHRS will never be chosen" [X Link](https://x.com/larrywabrams/status/1755324493206356475) 2024-02-07T20:15Z [----] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@larrywabrams Lawrence W. Abrams
Lawrence W. Abrams posts on X about cvs, $cvs, $chrs, $ci the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [---] -87%
- [--] Month [------] +826%
- [--] Months [------] -13%
- [--] Year [------] -26%
Mentions: [--] #
Followers: [-----] #
- [--] Week [-----] +0.10%
- [--] Month [-----] +0.87%
- [--] Months [-----] -2.20%
- [--] Year [-----] -1.80%
CreatorRank: undefined #
Social Influence
Social category influence stocks finance technology brands cryptocurrencies countries social networks celebrities currencies automotive brands travel destinations
Social topic influence cvs, $cvs, $chrs, $ci #36, $alvo, $wba, $rad, $googl, insurance, $amzn
Top accounts mentioned or mentioned by @ftc @stanmehr @costplusdrugs @bmadden4 @mattbiotech @cvshealth @qniatof @stocksdd @sherman1890 @truepillrx @daytonpubpolicy @sandozglobal @drugchannels @mintzlaw @biohazard3737 @bengolub @hashgraph @d1fund @stevewagsinvest @rabbiwolpe
Top assets mentioned CVS Health Corp (CVS) Cigna Corp (CI) Alvotech Ordinary Shares (ALVO) Walgreens Boots Alliance Inc (WBA) Radworks (RAD) Alphabet Inc Class A (GOOGL) Amazon.com, Inc. (AMZN) Dutch Bros, Inc. (BROS) Amgen, Inc. (AMGN) Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Eli Lilly and Company (LLY) AbbVie Inc (ABBV) UnitedHealth Group (UNH) McKesson Corporation (MCK) GoodRx Holdings, Inc. (GDRX) Pfizer, Inc. (PFE) Apple, Inc. (AAPL) Microsoft Corp. (MSFT) Hims & Hers Health, Inc. (HIMS) Walmart, Inc. (WMT) Marvell Technology Inc (MRVL) Cencora, Inc. (COR) Novartis AG (NVS) Merck & Co., Inc. (MRK) Lithium (LITH) Novo-Nordisk (NVO) Moon Tropica (CAH) Origin Protocol (OGN) The Bancorp Inc. (TBBK) NVIDIA Corp. (NVDA) Bitcoin (BTC) Bristol-Myers Squibb Co (BMY) Gilead Sciences, Inc. (GILD) Synthetify (SNY) RELX PLC (RELX)
Top Social Posts
Top posts by engagements in the last [--] hours
"@FTC about to settle with #PBMs $CI ESI in insulin list price collusion case -- Weak due #SCOTUS ruling in Twombly (2007) that parallel conduct alone insufficient for antitrust liability. To avoid summary judgement against plaintiff must prove overt agreement to collude is plausible not merely possible. Need "smoking gun" emails among CEOs in [----] to collude. See my paper 🔽 https://twitter.com/i/web/status/2014825810922995767 https://twitter.com/i/web/status/2014825810922995767"
X Link 2026-01-23T22:21Z [----] followers, [---] engagements
"@ElysiumEffect $MSFT Maia [---] announcement 8:01 AM. $MRVL spike 8:00 AM"
X Link 2026-01-26T18:29Z [----] followers, [---] engagements
"@FTC collusion case against Big [--] #pbms $CI $CVS $UNH and Big [--] insulin mfg $NVO $LLY $SNY weak as parallel list pricing along insufficient for "unfairness" or antitrust liability. Need "smoking gun" evidence of explicit emails among CEOs in [----] (see my article pin-pointing this date. 🔽 https://twitter.com/i/web/status/2016992232184930476 https://twitter.com/i/web/status/2016992232184930476"
X Link 2026-01-29T21:49Z [----] followers, [---] engagements
"This generations PayPal mafia picture. $NVDA $TSMC $MU Taiwan AI supply chain in one picture. https://t.co/ueTPDXnsRP AI supply chain in one picture. https://t.co/ueTPDXnsRP"
X Link 2026-01-31T18:00Z [----] followers, [---] engagements
"@MostroGrowth Some uncertainty over whether $MRVL can be a supplier to both $MSFT and $AMZN . Maybe best go all in with one"
X Link 2026-02-01T23:09Z [----] followers, [---] engagements
"New #meme word "orchestrator" as in "I am good at orchestrating my kids' Saturday schedule" or "I need you to better orchestrate dinner honey" #ai #code #Software"
X Link 2026-02-03T21:39Z [----] followers, [--] engagements
"@semivision_tw What companies will benefit and what period [----] [----] Vs after $MRVL Coherent Lightmatter"
X Link 2026-02-04T16:35Z [----] followers, [---] engagements
"$AMZN moving to partner with OpenAI on models inevitably leading to EXCLUSIVE use of their agents within their shopping walled garden sets up antitrust Sherman [--] and [--] down the road not to mention agency issues"
X Link 2026-02-04T18:36Z [----] followers, [---] engagements
"@Mr_Derivatives @grok summarize @Mr_Derivatives stock calls for past two weeks compared to what price is now"
X Link 2026-02-05T02:46Z [----] followers, [--] engagements
"@danielisdizzy @grok compare @danielisdizzy stock picks from January [--] [----] to February [--] [----] with the price they are at now with % change"
X Link 2026-02-05T02:54Z [----] followers, [--] engagements
"Call it The Saylor Contagion : A major buyer of $MSFT convertible debt is Calamos Investments with a number of bitcoin backed EFT. Watch run to liquidate these EFTs halted by Calamos triggering run to withdraw from other funds / financial institutions remotely associated with bitcoin. $BTC https://twitter.com/i/web/status/2019546873414156788 https://twitter.com/i/web/status/2019546873414156788"
X Link 2026-02-05T23:01Z [----] followers, [---] engagements
"Call it The Saylor Contagion : A major buyer of $MSTR convertible debt is Calamos Investments with a number of bitcoin backed EFT. Watch run to liquidate these EFTs halted by Calamos triggering run to withdraw from other funds / financial institutions remotely associated with bitcoin. $BTC https://twitter.com/i/web/status/2019575959922569723 https://twitter.com/i/web/status/2019575959922569723"
X Link 2026-02-06T00:56Z [----] followers, [---] engagements
"Ad in current issue of @NewYorker by $BMY touting checkpoint inhibitor combo of PD-1 Opdivo + CTLA-4 YERVOY. INHO $BMY desperately needs a safe synergistic second gen CD47 from $TRIL to go with Opdivo not a CTLA-4 with serious side effects"
X Link 2020-06-30T03:32Z [----] followers, [--] engagements
"2026 prediction: drug distributors $COR $CAH $MCK planning to carve out combined Rx healthcare benefit driven in part by biologic infusions (covered by medical benefit) now producing close substitute (newly patented) self-injectables (now covered by #PBMs benefit). A threat to $CVS $UNH $CI https://twitter.com/i/web/status/2018806505907331286 https://twitter.com/i/web/status/2018806505907331286"
X Link 2026-02-03T21:59Z [----] followers, [---] engagements
"@PhotonCap Can you map the same partners in OCS for $MSFT $NVDA $AMZN"
X Link 2026-02-04T17:00Z [----] followers, [---] engagements
"$CI #PBMs unit Express Scripts just settled insulin collusion case with @FTC . At glance looks like ESI reseller margins would take a big hit yet Wall Street doesnt see it that way maybe too early🙁"
X Link 2026-02-04T17:45Z [----] followers, [---] engagements
"@costplusdrugs and $GDRX - cash pay retail and mail order Rx- losers in @FTC settlement with $CI #pbms ESI moving to coinsurance and copays based on net prices not gross retail prices"
X Link 2026-02-04T18:27Z [----] followers, [---] engagements
"@FTC settlement with #PBMs ESI unit of $CI basically changes biz model -- still opaque -- from rebates and spread pricing to % fee based on each net priced Rx aggregated to PMPY trend. Given ESI ok with it I estimate new biz model at same 8% gross profit margin but now % of PMPY = $190 PMPY fee equivalent at [----] trend of around $2370 1/n https://twitter.com/i/web/status/2019138070931759553 https://twitter.com/i/web/status/2019138070931759553"
X Link 2026-02-04T19:56Z [----] followers, [---] engagements
"@PhotonCap I found these OCS partners listed on $NVDA page. Problem I find as investor is estimating timeline of actual ramp up of OCS by big [--] $MST $NVDA $AMZN . Looks like [--] years at least before any P&L impact smaller partners"
X Link 2026-02-04T21:17Z [----] followers, [----] engagements
"Up next after #Anthropic provides #AI alternative to Lexis/Nexis $RELX is government antiquated PACER . Indeed all government provided UX to data is up for disruption . 👍"
X Link 2026-02-10T18:31Z [----] followers, [---] engagements
"Apparently a thing at Columbu Ohio weddings - #osu #BuckeyePride"
X Link 2025-08-03T00:33Z [----] followers, [---] engagements
"Some thoughts on pending @FTC and $CI Express Scripts #PBMs settlement: a containment win for ESI limiting remedy to best effort to negotiate low list prices on legacy insulin drugs and no spread pricing on same drugs. No general remedy for opaque reseller business models now dependent on renamed formulary fees instead of rebates https://twitter.com/i/web/status/2014412178036818043 https://twitter.com/i/web/status/2014412178036818043"
X Link 2026-01-22T18:57Z [----] followers, [---] engagements
"@SanCompounding Can you explain difference in PE (2026) $MRVL vs $ALAB Marvell ( $MRVL ) -8% YTD PE(2026): 27.7x Astera Labs ( $ALAB ) -9% YTD PE(2026): 64.1x"
X Link 2026-02-02T18:33Z [----] followers, [---] engagements
"Maybe its because recent years PMPY trend driven more by utilization- especially GLP-1 and biologics - not net prices - #PBMs formulary management more about step therapy exclusions PA than rebate negotiations. $CI ESI willing to settle @FTC as rebates matter much less"
X Link 2026-02-04T17:53Z [----] followers, [---] engagements
"Now copayment and coinsurence based on net prices reduces payments to plan sponsors. I guestimate this could amount to as much as 2% PMPY trend = $47 PMPY. Not small potatoes given total ffe equivalent of PMPY payments to #PBMs is 8% = 25% of ffs equivalent paid Plus less copay = more utilization = more plan sponsor costs 2/n"
X Link 2026-02-04T20:05Z [----] followers, [---] engagements
"Still opaque $CI #pbms Express Scripts biz model move to % fees based on net prices which aggregates to % PMPY trend shifts #PBMs advocaries from #Pharma and drugstores to plan sponsors who won't like loss of copays and higher and higher PMPY trend 3/n"
X Link 2026-02-04T20:11Z [----] followers, [---] engagements
"Per @drugchannels #PBMs recent PMPY trend driven by utilization not net prices -- mostly GLP-1 and self-injectable biologics. Expect 14% YoY PMPY trend to continue now net price based lower copays and #Pharma offering self-injectable alternative to medical benefit infusions for Remicade Humira Keytruda. 4/n"
X Link 2026-02-04T20:32Z [----] followers, [---] engagements
"Significant $CI ESI #PBMs first to settle insulin collusion case with @FTC In some ways strongest of Big [--] #PBMs to weather any instability in transition of one opaque biz model -- retained rebates spread pricing -- to another- "data" "price protection" "placement" formulary fees expressed as a % of net prices (instead of % off WAC) aggregated to PMPY trend 5/n https://twitter.com/i/web/status/2019148298171609487 https://twitter.com/i/web/status/2019148298171609487"
X Link 2026-02-04T20:37Z [----] followers, [---] engagements
"@DrugChannels @FTC Big [--] killer move by $CI #PBMs ESI to offer 2027-8 -- transparent FFS biz model around $250 PMPY with trend guarantees and variance gain and loss sharing. See my PBM insurance biz model paper on this 🔽 6/n"
X Link 2026-02-04T20:44Z [----] followers, [---] engagements
"Nice summary by @Mintz_Law of proposed DoL #PBMs fee disclosure rule for employer self-insured plans -- will accelerate move toward full insurance biz model -- either MLR or FFS with PMPY trend guarantees. See my paper on this 🔽 https://t.co/TjsU8MFvJb #PBMS #health #labor @Mintz_Law https://t.co/ZHThB4XNVZ https://t.co/TjsU8MFvJb #PBMS #health #labor @Mintz_Law https://t.co/ZHThB4XNVZ"
X Link 2026-02-11T00:53Z [----] followers, [---] engagements
"@matthewherper If #Pharma and Wall Street believed that Trump is going to actually sign an EO for International Reference Pricing In #PartB biotech stock index $IBI would be down 10%. Instead Trump just posing to get Pharma to donate more to re-election campaign"
X Link 2019-07-05T20:02Z [----] followers, [--] engagements
"$CHRS will have a new #biosimilar competition from $NVS Sandoz. Will have to fight very hard to reach and maintain a 20% share. IMHO [----] revenue will not exceed $500M with flat QtoQ revenue after Q1. Stock is fairly priced now According to Biocentury @Sandoz's WAC price for #Ziextenzo will be $3925 approximately 9% less than that for #Udenyca and #Fulphila and 37% below #Neulasta's WAC. #biosimilars https://t.co/0qtaQ0Yv8C According to Biocentury @Sandoz's WAC price for #Ziextenzo will be $3925 approximately 9% less than that for #Udenyca and #Fulphila and 37% below #Neulasta's WAC."
X Link 2019-11-15T15:53Z [----] followers, [--] engagements
"1/2 While CTLA-4 still leads combo trials with PD-1/L1 the toxicity of Yervoy has caused the leaders -- $MRK $BMY $RHHY $AZN -- to look for new combos -- CD47 and TIGIT -- That's why $GILD called its acquisition of $FTSV "foundational" The future is bright for $TRIL $CGEN"
X Link 2020-05-17T18:46Z [----] followers, [--] engagements
"$CHRS not good that CFO resigns effective 3-7 then appoints communications guy. Likely due to terrible QoQ net sales decline which I have forecasted at 18.2% due to #pegfilgristim #biosimilar pricing pressure from new entrants $NVS (Sandoz) and $PFE [----] will be bad"
X Link 2021-02-17T21:11Z [----] followers, [--] engagements
"$SHMP up 20% in [--] days. IMHO NASDAQ listing within 2-3 weeks which makes it eligible for listings on StockTwits buying on Robinhood investing by micro cap funds. Fully grown shrimp for sale in 4Q21. More upside potential than $AASZF and $AQB"
X Link 2021-06-16T23:31Z [----] followers, [--] engagements
"@Biohazard3737 @PreparedRemarks @tomicki Characterizing $CHRS as adapting to market 2018-2021. I would call transition from Made In America value priced Udencya to China trial / China licensed late entrants checkpoint inhibitors a COMPLETE ABOUT FACE"
X Link 2022-01-15T21:22Z [----] followers, [--] engagements
"@Biohazard3737 @PreparedRemarks @tomicki Instead of your view of buying $CHRS now a cheap CALL option on multiple billion dollar PD-1 market I could see it as a PUT option on FDA rejection of BLAs based on poorly designed China only trials"
X Link 2022-01-15T21:26Z [----] followers, [--] engagements
"@Sanctuary_Bio $GILD not doing great with its oncology acquisitions $FTSV CD47 checkpoint inhibitor and $KITE autologous CAR-T Yescarta. Up next maybe is NK cell therapy $FATE $GMDA or preclinical $IPSC and $CELU Ha Ha for what they paid for $KITE they could buy all 4"
X Link 2022-01-26T04:31Z [----] followers, [--] engagements
"$AMZM purchase of One Medical is all about software and synergies: Watch them threaten Big [--] #PBMs by rolling out a narrow network pharmacy benefit where narrow is One Med Drs driving PMPY drug spend 20% below Big [--] or about $850 PMPY"
X Link 2022-07-21T17:09Z [----] followers, [--] engagements
"@chrissyfarr $AMZM purchase of One Medical is all about software and synergies: Watch them threaten Big [--] #PBMs by rolling out a narrow network pharmacy benefit where narrow is One Med Drs driving PMPY drug spend 20% below Big [--] or about $850 PMPY"
X Link 2022-07-21T18:40Z [----] followers, [--] engagements
"Like Rocky and Adrian $CHRS selling Lucentis biosimilar Cimerli to $SDZNY (Sandoz) "fills each other's gaps" = $CHRS fills cash gap Sandoz fills pipeline gap with anti-VEGF drug to sell now and could save $100M in R&D by dropping own development Avastin & Eylea #biosimilars"
X Link 2024-01-22T20:40Z [----] followers, [----] engagements
"Watch in a year $CHRS and $SDZNY (Sandoz) do a another "fills each other's gaps" deal where $CHRS fills cash gap again by selling its complete Udenyca array of injectables for say $250M+. Sandoz fills OBI gap in pegfilgrastim offerings now only with in-office infusion Ziextenzo"
X Link 2024-01-22T20:58Z [----] followers, [---] engagements
"Another 2nd guessing Landfear tweet: $CHRS core competency is its marketing team's ability to gain great market share in the Dr assisted buy & bill markets across diverse #biosismilars. Why pivot to Rx self-injectables Humira and PD-1 Tori Why not stay the course with Stelara"
X Link 2024-01-25T01:45Z [----] followers, [---] engagements
"I'll answer my own question: $CRHS CEO big ego drove him put addressable market over core competency as #1: Humira market $21B in [----] PD-1 market they say will be $139 B in [----]. Whereas Lucentis market was only $2.1 B in [----] and Stelara market will be about $10.5 B"
X Link 2024-01-25T01:52Z [----] followers, [---] engagements
"In [----] $ABBV still had Humira 95%+ share and $12B net revenue despite #biosimilars . Maybe one from $AMGN $ALVO $OGN $CHRS $SDZNY will get 10% of est $10B [----] and $8B [----]. Rest are 2% ers -- $200M in [----] and $160M in [----] market. There will be a lot of disappointed investors"
X Link 2024-02-05T00:50Z [----] followers, [----] engagements
"In the future could $CVS continue to private label reference drugs losing patent protection -- Enbrel Prolia Zolair -- invoking interchangeable thereby earning mfg markups while denying rebates to Optum and ESI whenever a reference still covered by Optum and ESI comes in"
X Link 2024-02-08T00:44Z [----] followers, [---] engagements
"Also anyone know about the legality of "backwards" interchangeability - pharmacists exchanging a lower cost reference like a $CVS Codavis private label Humira for an Rx for #biosimilars like $SDZNY Hyrimoz or BI's Cyltezo or $AMGN Amjevita @StanMehr"
X Link 2024-02-08T01:04Z [----] followers, [---] engagements
"The issue of safety and USA reliance on China #biosimilar CMOs like WuXi Biologics begs the question of who is $CHRS CMO for Humira biosimilar Yusimry Their 10-K recognizes risks of CMOs but is not specific. Name of CMO inspected for BLA for CHS-1420(Yusimry) is redacted"
X Link 2024-03-06T18:48Z [----] followers, [---] engagements
"@avidresearch Given Humira at time was HC why in early days of planning 2018-19 some cos choose HC ( $SDZNY $ALVO ) while other chose LC ( $AMGN $CHRS BI ) What was $CHRS thinking A slam dunk I guess given as late as Nov [----] still projecting 1.2B revenue in 2026"
X Link 2024-05-09T19:33Z [----] followers, [---] engagements
"@MattJMcClintock Should compare traffic at dedicated cosmetics stores: Sephora vs $ULTA or any front of store at a drug store chain"
X Link 2024-05-29T06:10Z [----] followers, [----] engagements
"@minchoi I took Its over metaphorically to mean AI saying Its over to Hollywood. NOT. AI at sunday comic strip stage. Long way to go before a full length movie with compelling plot twists and actors/ actresses"
X Link 2024-08-30T17:53Z [----] followers, [----] engagements
"12000 sq ft drugstore model is obsolete. Witness decline of $WBA $CVS $RAD retail. Future of Rx retail is cheap land converted to drive-in + tele-pharmacist from mobile phone + robot delivery. Also watch #PBMs sell off retail Rx claims adjudication to distributors $COR $MCK $CAH https://twitter.com/i/web/status/1875229370274767160 https://twitter.com/i/web/status/1875229370274767160"
X Link 2025-01-03T17:14Z [----] followers, [----] engagements
"Why is $ALVO down 7.4% so far today IMHO it is a reaction to a Formycon PR that it will take about a $100 Million balance sheet write down of its purchase of a biosimilar to Stelara due to now perceived intense rebate competition off WAC for #PBMs formulary positions. This implies $ALVO projected net revenue from its own Stelara biosimilar SELARSDI is way too high"
X Link 2025-02-19T19:36Z [----] followers, [---] engagements
"No. Always danger of short squeeze due to 63% of outstanding stock owned by holding companies controlled by $ALVO founder Robert Wiseman former CEO of Actavis. Their self-injectable #biosimilars partnership with $TEVA is falling way short due to intense competition for #PBMs favored formulary positions. Humira biosimilar - failure. Upcoming Stelara biosimilar -- will have to compete with [--] others"
X Link 2025-02-19T20:22Z [----] followers, [---] engagements
"$ALVO besides LT debt of $960M it has LT debt of $530.5 M in "Derivative Financial Liabilities" These are bond bondholder warrants to convert to stock $10 and pre-IPO stock holders warrants to purchase stock anytime after [--] days stock $15. GAAP demands liability still on books but 😂 really worthless given prospect for their biosimilars for Humira and Stelara with [--] competitors"
X Link 2025-02-19T22:44Z [----] followers, [---] engagements
"Agree to disagree. Check out this [--] year stock chart of another biosimilar co $CHRS. I was down on them since [----]. They did a great job for a while gaining share from reference drugs but ultimately competition for #PBMs formulary positions drove down net prices after rebates. Here is $CHRS [--] year chart. IMHO $ALVO will match this 2025-2029 as its failure to gain significant market for its biosimilars for Humira Stelara Eylea become apparent"
X Link 2025-02-20T01:59Z [----] followers, [---] engagements
"Turns out Denny was smart to get out of biosimilars when he did. In hindsight it was a great deal for $CHRS to sell off Cimerli for $170M to Sandoz. Recent PR by Formycon that it marketing partner Sandoz may "pause" Cimerli marketing due to extreme rebating for formulary positions causing net unit prices to plummet"
X Link 2025-02-20T02:19Z [----] followers, [---] engagements
"@caseymeekMD check out this [--] day chart for another biosimilar company $FYB down 41.5% due to PR rethinking its commercialization strategy for biosimilars for Stelara (Otulfi) and Lucentis (Cimerli) and associated write-offs. Investors are terribly naive about the ability of the Big [--] PBMs to extract rebates for favored formulary positions. IMHO Biosimilar companies are not good long term investments Dr. Casey Meek MD https://twitter.com/i/web/status/1892402465565499424 https://twitter.com/i/web/status/1892402465565499424"
X Link 2025-02-20T02:34Z [----] followers, [---] engagements
"why $WBA and $RAD failed now Not because of Rx margin squeeze by #PBMs but long time decline in front store convenience traffic due to online and tired merchandising. Future of [-----] sq ft drugstore model is dead. Sycamore PE has to be studying $BROS and Chick-fil-A four lane drive up model no walk-in https://twitter.com/i/web/status/1900634638911168875 https://twitter.com/i/web/status/1900634638911168875"
X Link 2025-03-14T19:46Z [----] followers, [---] engagements
"My formulary auction design model reframing of $AMGN Amgen's use of bundled rebates for Repatha to exclude $REGN Regeneron's Praulent -- $CI #PBMs Express Scripts just as liable for allowing a non-standard formulary position bid basis -- where standard rebate basis is a single % off WAC 1/2 https://twitter.com/i/web/status/1923476637661921683 https://twitter.com/i/web/status/1923476637661921683"
X Link 2025-05-16T20:32Z [----] followers, [---] engagements
"@costplusdrugs Mark Cuban saying his company @costplusdrugs is trying to disrupt the Big [--] #PBMs by signing a deal with grocery chain is laughable. Only way to beat the #PBMs is will be for some BCBS to offer a FFS plan at around $150 PMPY FFS and guaranteed trend of $2000 PMPY + shared risk for variations"
X Link 2025-08-09T23:11Z [----] followers, [--] engagements
"@megangrA Per white paper In Google #antitrust search case .reconstructing a world but for the anticompetitive conduct of the monopolist is nearly if not totally impossible. Uh no see my "but-for" counterfactual and link to my paper below"
X Link 2025-08-21T21:57Z [----] followers, [---] engagements
"@Econ_4_Everyone @ben_golub A counterfactual field experiment is needed namely test for switching over time where there is NO change in available substitutes or nature of initial substitutes. i.e how much switching is due to sheer boredom with choice"
X Link 2026-01-01T20:55Z [----] followers, [---] engagements
"@manthanguptaa One implication seem to be that the architecture for Agentic memory will be fundamentally different than the Transformer neural network for LLMs. If separate any thoughts on how the two will be connected Will I be able to transfer my own long term memory to another LLM"
X Link 2026-01-04T23:17Z [----] followers, [--] engagements
"@manthanguptaa Interoperability between personal Agentic memory and LLMs has major implications for competitive landscape. Why would a startup develop an Agentic memory separate from an LLM if there were no way to connect in an efficient safe manner"
X Link 2026-01-04T23:23Z [----] followers, [--] engagements
"Legacy systems of record are threatened by startups who can tap in via API and build AI agents who develop decision traces which become the new system of record for decision making. E.g. Manus tapping into Slack"
X Link 2026-01-07T17:50Z [----] followers, [---] engagements
"2026 Prediction - the Enterprise job title AI Prompt Engineer will be superseded by AI Context File Engineering as now Cursor stores context as files. The agent loads details only when it needs them just like a developer opens a file only when required. #AI @cursor_ai"
X Link 2026-01-07T18:39Z [----] followers, [--] engagements
"@FoundationCap got it right. The road to full autonomous Agentic AI will be for startups to access Enterprise decision making (ala #Palantir) and post-train LLMs to build decision traces which then becomes the brains for point solutions to tasks. $Meta buying Manus for $2 Billion just the beginning. There will be scores of this acquisitions in [----]. https://twitter.com/i/web/status/2008979492262334889 https://twitter.com/i/web/status/2008979492262334889"
X Link 2026-01-07T19:10Z [----] followers, [--] engagements
"The race to the bottom: $Hims will be threatened by AI first startups licensed by states to fill lifestyle and weight loss Rx"
X Link 2026-01-07T19:28Z [----] followers, [---] engagements
"@ashpreetbedi Only problem is that legacy systems of record (SORs) will realize what you are doing is a big threat as your build up of decision traces plus new prompt window becomes the new UX . Will start blocking API access to SORs. #antitrust"
X Link 2026-01-07T20:27Z [----] followers, [---] engagements
"Wonder how receptive $PLTR and Enterprise SaaS companies like $ORCL and $CRM will be to startups offering point solution Agentic AI"
X Link 2026-01-08T04:59Z [----] followers, [---] engagements
"Another [----] #AI prediction involving the Big [--] #PBMs $CVS $UNH $CI versus the Big [--] Drug Distributors $COR $CAH $MCK"
X Link 2026-01-18T21:47Z [----] followers, [---] engagements
"Opportunity for #AI #Startups : Big [--] #PBMs haven't rolled out yet automatic Rx adherence feedback connecting Rx prescribed with fills -- then emails to Drs and patients when adherence lags -- Why not more Rx = more $$ to PBMs. Good for employers too as Rx adherence saves treatment costs🫤 https://twitter.com/i/web/status/2014821264926589341 https://twitter.com/i/web/status/2014821264926589341"
X Link 2026-01-23T22:03Z [----] followers, [---] engagements
"The sh*t is about to hit the fan for CMS @RobertKennedyJr @DrOz as the new Maximum Fair Price (MFP) reimbursement system for [--] drugs between Pharma and retail pharmacies has not be fully implemented. See December [----] letter full link 🔽 #drugpricing #PBMs"
X Link 2026-01-26T01:45Z [----] followers, [---] engagements
"Letter by Senators to @RobertKennedyJr @DrOz on new Part D Maximum Fair Price reimbursement plan snafu https://www.lankford.senate.gov/wp-content/uploads/2025/12/2025-12-11-Senate-MFP-Effectuation-Letter-to-CMS-HHS.pdf https://www.lankford.senate.gov/wp-content/uploads/2025/12/2025-12-11-Senate-MFP-Effectuation-Letter-to-CMS-HHS.pdf"
X Link 2026-01-26T01:47Z [----] followers, [--] engagements
"@SanCompounding Announced 8:01 AM . $MRVL stock spike 8:00 AM"
X Link 2026-01-26T18:24Z [----] followers, [---] engagements
"@bobkolker liked your piece on MZ and Gabriel Leydon -- here is a recent blog post I did on them -- http://t.co/QFuT7ZpEJO http://glomoinvesting.com/machine-zone-the-4-billion-unicorn-that-walks-the-walk/ http://glomoinvesting.com/machine-zone-the-4-billion-unicorn-that-walks-the-walk/"
X Link 2015-03-27T18:43Z [----] followers, [--] engagements
"#PBMs formularies are a "Google" away. In a week $CVS and $ESRX will release their 2019s. I like to speculate about what formulary choices imply about the rebate game. Must see game this year will be basal insulins. Go @LillyPad .compete on list price for once with Basaglar"
X Link 2018-07-27T01:15Z [----] followers, [--] engagements
"Note to Pharma: if you are a late entrant to a therapeutic class you will not get coverage by playing the PBM rebate game. Must target niches with low list = lowest net = no rebate. $Abbv doing it with #Mavyret. Set to end #HepC among Vets. Free testing. Prisoners next"
X Link 2018-08-04T20:58Z [----] followers, [--] engagements
"1/ What did CEO of $MRK Ken Frazier mean by the possibility of a disintermediation in the pharmaceutical industry that can make drugs more affordable My take: $MRK goes to high list but no rebates to #PBMs get excluded initially by #PBMs on national formulary Then"
X Link 2018-10-05T02:26Z [----] followers, [--] engagements
"$RAD $1 share will be delisted in [--] days. Only options : reverse split or sell #PBM unit #EnvisionRx In death spiral now"
X Link 2018-12-19T17:13Z [----] followers, [--] engagements
"@tonysheng A NextGen MMO game will have a p2p trading platform based on pub-sub protocol. People will be able to stake sides in upcoming battle with winner take all sweepstake. Cash in for crypto game tokens. To avoid anti-gambling laws no cash out but can donate tokens to charity"
X Link 2019-01-09T17:07Z [----] followers, [--] engagements
"Agree that drug supply chain IS in turmoil but relatively speaking its not #PBMs but retail drugstores fill margins squeezed by #PBMs and $AMZN killing front store traffic. $RAD is zombie $WBA worst Q financials since [----]. $CVS desperate to reposition front store"
X Link 2019-04-07T16:40Z [----] followers, [--] engagements
"Ive been hoping for years for healthcare startups like @OscarHealth or existing companies like $AMZN or to disrupt #PBMs. It looks like $MCK and $ABC are going to roll out claims processing alt to #PBMs that startups can plug into. Heck they may even have plans to become #PBMs"
X Link 2019-04-19T05:51Z [----] followers, [--] engagements
"End of an era: 2002-19 RIP my ability to analyze #PBMs $ESRX 10-K P&L now that its financials are conveniently scattered throughout $CI financials. Here is my last effort to convert FY2017 opaque gross profits to FFS equivalent plus estimate of equivalent medical loss ratio"
X Link 2019-05-03T02:34Z [----] followers, [--] engagements
"$Teva stock price goes up from 63% $37 trough 12-2012 to $64 peak 6-2015 to corroborate #drugprices fixing allegations . But similar stock rise for $WBA at 98% - $41 to $81. Likely collusion by oligopsony buy-side double Big 3s (drugstores & #PBMs) to divvy up rents"
X Link 2019-05-13T04:47Z [----] followers, [--] engagements
"$AMZN time to buy $RAD stop trying to get BCBSs or #PBMs to add PillPack to networks as @Prime_PBM LT contract with $WBA $ANTM LT contract with $CVS. Buy $RAD then pay off $3.5B debt. Get EnvisionRx PBM get bricks and mortar pharmacy convert front stores to Prime Clubs"
X Link 2019-06-23T23:03Z [----] followers, [--] engagements
"Example of #oligopoly $FMS $DVA outsider following the rents and disrupting $CVS going into home #dialysis and fast turn around of lab testing $DGX $LH with state of the art online access by patients. https://www.bloomberg.com/news/articles/2019-07-17/cvs-pushing-into-kidney-dialysis-with-help-from-segway-inventor https://www.bloomberg.com/news/articles/2019-07-17/cvs-pushing-into-kidney-dialysis-with-help-from-segway-inventor"
X Link 2019-07-17T14:43Z [----] followers, [--] engagements
"Hopefully #3 and #4 who are outside of tight tri-opoly of $NVO $LLY $SNY will compete on list although completely disappointed with lack of list and net competition by $MYL with it biosimilar Fulphila. Currently there are just a handful of insulin biosims including the Lilly Lantus knockoff branded Basaglar and the Sanofi Humlog knockoff branded Admelog. A few are pending from Mylan/Biocon and others fr Novartis-Sandoz/Gan&Lee. But even with these there will be less than [--]. Currently there are just a handful of insulin biosims including the Lilly Lantus knockoff branded Basaglar and the"
X Link 2019-07-21T19:46Z [----] followers, [--] engagements
"$RAD should snap up Freds Rx accounts but not store leases"
X Link 2019-09-09T18:08Z [----] followers, [--] engagements
"Employees mgt at @hashgraph #Hedera have to be totally demoralized today as $10M In SAFT options purchased a year ago between $.096 and $.12 now underwater as HBAR trading opened on 9-16-19 at $.30.but today price is around at $.04"
X Link 2019-10-06T00:27Z [----] followers, [--] engagements
"#Hedera @hashgraph price discovery NOT over. Opened at $.36.now at $.04. SAFT a year ago $100M raised between $.096 and $.12 with valuation of 50B max HBAR limit at $6B. IMHO value today is basically money left in bank of approx $80M / 50B Max HBAR = $.016 CRASH"
X Link 2019-10-06T01:54Z [----] followers, [--] engagements
"$TBBK (The Bancorp) #fintech #mobilebanking customer Chime still having significant processing problems. Time for the @FDICgov to start an investigation. Also alert to investors in $TBBK: GET OUT"
X Link 2019-10-24T22:58Z [----] followers, [--] engagements
"Nice description by payroll processor @GustoHQ of how their ACH processing bank has a series of "sanity checks" to make sure accounts used "makes sense" Evidently both Cachet and $TBBK (The Bancorp) lacked "sanity checks" that would have detected the MyPayrollHR fraud"
X Link 2019-10-27T23:36Z [----] followers, [--] engagements
"Nice description by payroll processor @GustoHQ of how their #ACH processing bank has a series of "sanity checks" to make sure accounts used "makes sense" Evidently both @CachetFS and $TBBK (The Bancorp) lacked "sanity checks" that would have detected @MyPayrollHR fraud"
X Link 2019-11-11T18:31Z [----] followers, [--] engagements
"$BYD $LVS $WYNN $MGM. Looks like NV will open up Vegas way before CA Governor opens up SoCal. CA will need police to block I-15 from LA folks driving to Vegas for the weekend. Vegas will be major source of re-infection for CA if no NV - CA wall https://sfist.com/2020/04/14/newsom-lays-it-down-that-stay-at-home-orders-not-getting-lifted-anytime-soon/ https://sfist.com/2020/04/14/newsom-lays-it-down-that-stay-at-home-orders-not-getting-lifted-anytime-soon/"
X Link 2020-04-15T03:13Z [----] followers, [--] engagements
"Easy to overestimate potential TIGIT sales from biotechs like $MREO $AGEN $SURF $CGEN given big players also have TIGIT trials $BMY $RHHBY and Merck KGaA. IMHO key isn't TIGIT itself but the combo /trio it is paired with. My bet $CGEN see listing https://clinicaltrials.gov/ct2/resultsterm=TIGIT&cntry=US&draw=2&rank=2#rowId1 https://clinicaltrials.gov/ct2/resultsterm=TIGIT&cntry=US&draw=2&rank=2#rowId1"
X Link 2020-07-10T23:30Z [----] followers, [--] engagements
"$TRIL Jan closed call with statement that ASH gave TRIL ok to break embargo and release update to coincide with $PFE equity investment. Also there would be a further update now at ASH"
X Link 2020-09-08T22:22Z [----] followers, [--] engagements
"IF #California Governor @GavinNewsom were serious about travel restrictions he would have @CHPsouthern stop weekend travel between #LA and #vegas along the I-5 $MGM $WYNN $BYD"
X Link 2020-11-14T03:27Z [----] followers, [--] engagements
"$RBLX See my article on Roblox from THREE years ago https://www.google.com/amp/s/glomoinvesting.com/roblox/ https://www.google.com/amp/s/glomoinvesting.com/roblox/"
X Link 2020-11-26T15:32Z [----] followers, [--] engagements
"$IBKR stock up likely based on company reporting daily average revenue trade (DARTs) of $3295 up 223% YoY and 43% MoM. But IMHO market should also pay attention to report of client margin balance at $40.8 Billion up 49% YoY. Without expert risk management this is alarming"
X Link 2021-02-01T19:40Z [----] followers, [--] engagements
"$FTAC Payoneer #SPACs PR keep saying it's Betsy Cohen's SPAC. She is really a front for her son Daniel G. Cohen this generation's Enron "smartest guy in the room" See my paper on their $TBBK accounting https://medium.com/@larrywabrams/the-bancorp-a-test-for-post-enron-gaap-5b4881bd23bd https://medium.com/@larrywabrams/the-bancorp-a-test-for-post-enron-gaap-5b4881bd23bd"
X Link 2021-02-05T19:30Z [----] followers, [--] engagements
"$EVGN a [--] division mini Ginkgo Bioworks at 1% of the $20 Billion valuation SPAC $SRNGU reported has placed on Ginkgo. $EVGN s computational biology platform has produced synthetic bacteria in area of seed coating herbicides and Microbiome to boost oncology cell therapies"
X Link 2021-04-11T02:38Z [----] followers, [--] engagements
"$EVGN strength is a DISCOVERY platform and MIXING of microbes and bacteria in area of seed coating and gut Microbiome. Ginkgo Bioworks strength is sophisticated stitching together of microbes and bacteria relying on others for discovery. I like $EVGN at 1% valuation of $SRNGU"
X Link 2021-04-11T22:37Z [----] followers, [--] engagements
"$RHBBY "Sales in the Pharma Div decreased 9% to CHF [----] B mainly because of the continued biosimilars competition." I was [--] 1/2 years ahead in predicting meaningful #biosimilars competition. No need for statist policies advocated by @peterbachmd https://nu-retail.com/biosimilar-entry/ https://nu-retail.com/biosimilar-entry/"
X Link 2021-04-21T21:46Z [----] followers, [--] engagements
"$AMZN Pharmacy -- do not sell short its potential to disrupt #PBMs and bricks and mortar $CVS $WBA $RAD with a business model featuring loss leader SIX Month supply of generics for $1 a month offset by high margins on private label vitamins and beauty products"
X Link 2021-06-24T02:54Z [----] followers, [--] engagements
"Just test out $UNH new integrated Optum Store -- cheap Rx generics in-home testing kits teladoc. Has a slick UX. OTH $CI Express Scripts and $CVS online has a tired look offering only Rx. Lots of catching up to https://store.optum.com/ https://store.optum.com/"
X Link 2021-07-18T20:26Z [----] followers, [--] engagements
"$JNJ vs $PFE settle #antitrust lawsuit out of court re: lump sum rebate use in #PBMs formulary placement of reference vs #biosimilars. IMHO big win for competition vs competitors. #ChicagoSchool See my paper https://nu-retail.com/antitrust-biosimilars/ https://nu-retail.com/antitrust-biosimilars/"
X Link 2021-07-26T14:56Z [----] followers, [--] engagements
"$CVS is closing [---] stores. I predicted in [----] that $WMT $4 cash / Rx would be the beginning of the end of the drugstore business model of the pharmacy subsidizing the front store http://www.nu-retail.com/CVS_Caremark_Merger.pdf http://www.nu-retail.com/CVS_Caremark_Merger.pdf"
X Link 2021-11-19T20:14Z [----] followers, [--] engagements
"Table stakes for online pharmacies will soon become integrated Tele-Dr / Rx dispensing/ online delivery like new offering by $GDRX Take note: @costplusdrugs $HIMS @OptumRx and a host of startups"
X Link 2022-01-18T22:50Z [----] followers, [--] engagements
"$ICL Wall Street Journal article today on how Brazil seeking alternative sources of Potash from Canada now that sources from Russia and Belarus cut off. IMHO there is a mad rush now in Europe and India to sign potash contracts with $ICL out of Dead Sea IZ"
X Link 2022-03-29T21:07Z [----] followers, [--] engagements
"$RAD stock crash another sign that retail drugstore profitability -- chains and independents both -- are under stress by online both of Rx and front store stuff -- Politicians need to realize that eliminating #PBMs spread pricing will not save retail drugstores"
X Link 2022-04-07T21:23Z [----] followers, [--] engagements
"@Biotech2k1 Every decade in #Biotech there is a breakthrough technology that will enable a startup to "go the distance" (i.e. not be bought out) and become a 50x-100x. $AMGN and mAB in the early 00s was one -- iPSC NK ( $FATE $SANA and others ) could be the one to "go the distance" in 20s"
X Link 2022-04-30T03:43Z [----] followers, [--] engagements
"$KSS Kohl's buyout offer suggests $RAD Rite-Aid could next with parts -- real estate and Rx customer accounts -- worth more than current Enterprise Value (EV) of about $3.5B (MC + debt). Retail drugstore as convenience concept is dead with $RAD is the sickest $CVS $WBA"
X Link 2022-06-07T18:05Z [----] followers, [--] engagements
"@B_Madden4 @navituspbm @PrescryptiveH Really $AMZN wants One Meds software more than bricks and mortar. Ultimate goal is alternative end-to-end software platform to EHR Epic and Cerner eRx Surescripts and #PBMs POS formulary software. 1/2"
X Link 2022-07-22T05:29Z [----] followers, [--] engagements
"@B_Madden4 @navituspbm @PrescryptiveH $AMZN disruption via $OMED acquisition to Big [--] #PBMs will be (1) move formulary management to POC from POS (2) narrow network pharmacy benefit where narrow is One Med Drs reducing PMPY drug spend 20% to $850"
X Link 2022-07-22T05:33Z [----] followers, [--] engagements
"$DNA Ginkgo collaboration with Bayer in ag synthetic bio puts pressure on $CTVA to seal collab / investment in Lavie Bio subsidiary of $EVGN"
X Link 2022-07-25T21:01Z [----] followers, [--] engagements
"$UNH OptumRx #PBMs Optum Store (slick UX with @truepill_rx API) - just got email touting all the OTC therapeutics they offer - they make more gross profits on OTC than generic Rx hurt traffic at retail pharmacies. $CVS Caremark would never do this"
X Link 2022-10-20T15:36Z [----] followers, [--] engagements
"$UNH $AMZN understand this but startup online Rx fill and delivery cos like @costplusdrugs @GoodRx $GDRX $HIMS do not Margins are NOT in generic Rx but cross selling healthcare products and vitamins. See this Optum Store Twitter ad"
X Link 2023-01-27T16:36Z [----] followers, [---] engagements
"Good idea.but.while Netflix-like fixed $ / year subscription will lowers average cost of Hep C treatment the more the useage important NOT to include generous inflation protection clause and obtain sealed bids by more than two companies $ABBV and $GILD Rewarding to see our Netflix model with @BillCassidy on Hep C headed to nationwide program. Orig description here: https://t.co/YXz8LLMdE3 https://t.co/5g3Nosu7Wq Rewarding to see our Netflix model with @BillCassidy on Hep C headed to nationwide program. Orig description here: https://t.co/YXz8LLMdE3 https://t.co/5g3Nosu7Wq"
X Link 2023-03-08T21:48Z [----] followers, [---] engagements
"$CI #PBM Evernorth (aka Express Scripts) caving to critics by offering a FFS biz model with fixed $ copays no spread pricing 100% pass thru of rebates. Big Q is will they reveal FFS PMPY and target drug spend as PMPY Bet they wont reveal either - still not transparent"
X Link 2023-04-26T19:34Z [----] followers, [---] engagements
"$CI #PBM to offer new plan featuring fixed $ copay. $5 for generics $25 for preferred brand and $45 for preferred specialty injectable. If other big #PBMs follow people with insurance who had been paying cash at @costplusdrugs and $GDRX will return to Big [--] plans"
X Link 2023-04-26T19:41Z [----] followers, [---] engagements
"$GDRX and @costplusdrugs are doomed now that $CI #PBMs Express Scrips has caved to critics to offer now fixed $ copays. People with insurance will no longer find cash Rx prices lower than fixed $ copays that one of the Big [--] will offer. The other [--] will be pressured to match"
X Link 2023-04-26T19:54Z [----] followers, [---] engagements
"@varma_ashwin97 Contracting externality is for forcing #PBMs to apply bundled rebates for formulary position- $AMGN raising rivals $HZN fixed cost via tariff (rebate) to gain access to formulary position. See my paper on market design https://papers.ssrn.com/sol3/papers.cfmabstract_id=4387935 https://papers.ssrn.com/sol3/papers.cfmabstract_id=4387935"
X Link 2023-05-16T20:59Z [----] followers, [---] engagements
"@FTC right to target $AMGN -- leader in using bundled rebates to raise rivals costs creating negative margins. See [----] lawsuit by $RGEN where $AMGN bumped up rebates for Otelza and Enbrel if #PBMs chose Repatha and excluded $RGEN Praluent. See case"
X Link 2023-05-16T22:34Z [----] followers, [---] engagements
"@DaytonPubPolicy Wfh Bay Area also moving out of Santa Cruz and Aptos as it also has Bay Area home prices"
X Link 2023-05-17T03:12Z [----] followers, [--] engagements
"@Kevin_M_Biotech @BertrandBio Yes $AMGN reported 1Q23 sales of Enbrel down 33% because of price competition from therapeutic similar #biosimilars of Humira including their own"
X Link 2023-06-01T16:39Z [----] followers, [--] engagements
"@AnotherBio You are not alone. A bunch of retail $CHRS investors see the same thing. OTH $1 B revenue in [----] not sure thing. 50% chance $ABBV files breach of contract Tori get a CRL Cimerli 2Q23 revenue disappoints or CEO Lanfear stuffs channels again like he did with Udencya in 2019"
X Link 2023-06-26T04:56Z [----] followers, [---] engagements
"In just [--] days since acquisition of $SURF at $5.28 /share $CHRS stock has declined 28% to $3.80. Watch the number of class action lawsuits claiming breach of fiduciary duty on part of SURF management multiply. This deal will never close unless $CHRS kicks in $18+M in shares"
X Link 2023-06-27T18:16Z [----] followers, [----] engagements
"@DesatCap $WBA written about in Jim Collins book Good to Great in [----]. I felt they should have followed $CVS in 2010s and bought a #PBM . No they had a hedgehog strategy well look at the slow poke now- back to [----] low 🦔🦔🦔"
X Link 2023-06-27T19:51Z [----] followers, [--] engagements
"@qniatof @chaperonycon Sales data compiled by Symphony is based on WAC or gross prices not net after rebates. $26 M reported for Cimerli in June is gross sales. Net is likely 1/2 or $13 M . $CHRS projects $48-$52M NET for 2Q. Will just hit that with $26M net for Udenyca and $25M net for Cimerli"
X Link 2023-07-11T07:59Z [----] followers, [---] engagements
"@qniatof @chaperonycon Ha ha only two people awake at this time is me on the West Coast USA at [--] AM and you Chris in Sweden at [--] AM"
X Link 2023-07-11T08:04Z [----] followers, [---] engagements
"Blue Shield of CA dropping $CVS as #PBMs is definitely an attack on vertically integrated PBMs - cobbling together mail order from @costplusdrugs and $AMZN but still retaining suspect vendor for formulary and rebate Mgt Prime Therapeutics who outsources to Express Scripts"
X Link 2023-08-17T18:23Z [----] followers, [---] engagements
"$CVS $WBA today at all time lows. Not surprising. Front store was never very profitable Retail was due to generic margins holdup by #PBMs until $WMT started $4/Rx cash in [----]. Now even owned mail order not very profitable due to $AMZN & $GDRX competition (and PBM coverage)"
X Link 2023-08-17T19:57Z [----] followers, [---] engagements
"$CVS $WBA today at new lows. Not surprising. I predicted in [----] that $WMT $4/Rx cash would be start of an assault on the profitability of the drugstore business model eventually (longer than I thought) leading to drug stores following dime stores as retail dinosaurs"
X Link 2023-08-17T20:02Z [----] followers, [----] engagements
"My [----] paper predicting the effect of the $WMT $4/Rx on the Big [--] drugstore / #PBMs tacit collusion to hold up generic prices and the end of the drugstore business model of the back pharmacy subsidizing the front store $CVS $WBA"
X Link 2023-08-17T20:10Z [----] followers, [---] engagements
"Blue Shield CA CEO says in WSJ article that its cobbled together #PBMs replacement for $CVS Caremark includes Rx claims process Abarca. Who is Abarca A small "healthcare administrator" (Facebook page quote) out of Puerto Rico. This move has all the markings of a disaster"
X Link 2023-08-17T20:36Z [----] followers, [---] engagements
"$CVS getting into co-producing and marketing a low list private label biosimilar of Humira called Hyrimoz from Sandoz. Key to understanding strategy is knowing that Hyrimoz is only [--] of [--] interchangeable among [--] biosimilars for Humira 1/n"
X Link 2023-08-25T01:12Z [----] followers, [----] engagements
"No surprise -- CVS's main customer for private label Hyrimoz will be CVS retail drugstores whose pharmacists will exclusively "interchange" Hyrimoz for Humira Rx in states with laws that allow "interchangeables" without prior approval of prescribing Dr. 2/n"
X Link 2023-08-25T01:16Z [----] followers, [---] engagements
"This $CVS move to getting into the biosimilar INTERCHANGEABLE manufacturing and marketing business suggest that they see greater profit from biosimilar retail markups than retained formulary rebates from off-patent blockbusters biologic incumbents like Humira 3/3"
X Link 2023-08-25T01:23Z [----] followers, [---] engagements
"Note to @linakhanFTC :The motive for first mover vertical integration in drug supply chain is often to disrupt tacit collusions elsewhere to hold up margins: (1) CVS retail + Caremark #PBMs - created preferred provider networks breaking prior hold up of retail generic margins 4/n"
X Link 2023-08-25T01:31Z [----] followers, [---] engagements
"@linakhanFTC Note to @linakhanFTC : $CVS Health vertical integration with Sandoz to co-manufacturer and market of interchangeable biosimilars signals effort to move away from retained rebates dependent biz model to specialty drug retail margins biz model 5/5"
X Link 2023-08-25T01:36Z [----] followers, [---] engagements
"@Pharmdca $RAD value is in patient records that bankruptcy court can sell to $CVS and $WBA. Was a time years ago it could have sold leases but not now"
X Link 2023-08-25T16:36Z [----] followers, [---] engagements
"@Pharmdca My [----] SeekingAlpha calculations suggesting at time $RAD worth more closed than open due to value of patient accounts to $CVS and $WBA"
X Link 2023-08-25T16:40Z [----] followers, [---] engagements
"@StanMehr @CVSHealth @Sandoz_Global IMHO this moves is a signal that $CVS sees more future profits from on-invoice mfg to dispenser markups and #PBM to payer spreads on #biosimilars than off-invoice PBM retained rebates. Key here is CVS is backing an INTERCHANGEABLE biosimilar. 1/2"
X Link 2023-08-28T15:24Z [----] followers, [---] engagements
"@StanMehr @CVSHealth @Sandoz_Global By co-mfg an interchangeable biosimilar $CVS is capitalizing on its power to switch Humira Rx to its own product at POS without Dr prior approval earning double margin (1) mfg markup (2) PBM spread"
X Link 2023-08-28T15:30Z [----] followers, [---] engagements
"@StanMehr @CVSHealth @Sandoz_Global $CVS getting into the co-mfg of an INTERCHANGEABLE #biosimilar represents the final step in an complete vertical integration of Rx - owned mfg to owned specialty distributor to owned retail managed by owned #PBM as agent for owned insurance company"
X Link 2023-08-28T15:52Z [----] followers, [--] engagements
"@StanMehr @CVSHealth @Sandoz_Global Ha ha $CVS by owning all levels of Rx - mfg distribution dispensing PBM insurance- is able to shift profit center to another level if government steps up regulation of any one"
X Link 2023-08-28T15:58Z [----] followers, [--] engagements
"@StanMehr Sad that Medicare Part D has autoimmune drugs as a protected class preventing switching of Humira and it biosimilars for Enbrel in certain indications. $CVS in his commercial formulary has Humira AND Enbrel covered in [--] of [--] indications"
X Link 2023-08-29T16:54Z [----] followers, [--] engagements
"@rachelcohrs Sad that Medicare Part D has autoimmune drugs as a protected class preventing switching of Humira and it biosimilars for Enbrel in certain indications. $CVS in his commercial formulary has Humira AND Enbrel covered in [--] of [--] indications"
X Link 2023-08-29T16:58Z [----] followers, [--] engagements
"@D1Fund @SteveWagsInvest $CHRS Dont expect much Yusimry (Humira #biosimilar sales from @costplusdrugs much hype not enough customer adoption no scale running out of funds Cuban no deep pockets use API software from @truepill_rx which has had [--] layoffs cuz other online Rx co also losing money"
X Link 2023-08-31T20:49Z [----] followers, [----] engagements
"@qniatof @D1Fund @SteveWagsInvest @costplusdrugs @truepill_rx All new online Rx GoodRx Cuban struggling with profitability. Humira market $21B in [----] but maybe $10B in [----] due to price drops so $CHRS 4% sound great at $400M relative to today butprofit positive cash flow On road to [----] minimum revenue goal of $1.2B No"
X Link 2023-09-01T16:12Z [----] followers, [--] engagements
"@qniatof @D1Fund @SteveWagsInvest @costplusdrugs @truepill_rx $CHRS facing fast dropping Humira price market. $21B in [----] maybe $10B in [----] so 4% share= $400 M is great but by [----] Humira market likely $4B so 8% share is $320M in short $CHRS will NOT reach its [----] minimum revenue goal of $1.2B"
X Link 2023-09-01T16:26Z [----] followers, [---] engagements
"$WBA CEO and CFO leaving suddenly $RAD planning bankruptcy. This isn't because of opioid lawsuits but death of the retail drugstore business model -- declining profits from Rx fill and increasing losses from front store due to $AMZN and online"
X Link 2023-09-01T23:58Z [----] followers, [---] engagements
"@a4floridacajun Yes #PBMs unions agricultural grain storage co-ops are all middlemen by as seen by that insightful neoliberal economist in the 50s as countervailing powers to oligopolies capturing rents and passing it on to consumers in form of lower prices or higher wages. 1/n"
X Link 2023-09-06T04:45Z [----] followers, [---] engagements
"@JulieChangRE @realest49919420 Tyler Childers Morgan Wallen Zach Bryan Jason Isbell Bradley Zimmerman Lainey Wilson Jelly Roll"
X Link 2023-09-14T01:07Z [----] followers, [---] engagements
"@ChickenJoeSTL At least locally owned Bus Loop Burgers survived and thrives in new but uninspiring strip mall in St. Ann. Too bad not more name restaurants in StL City couldnt keep legacy going in new albeit faceless suburban locations"
X Link 2023-09-14T19:59Z [----] followers, [--] engagements
"@JKGY42686232302 @qniatof No crafty CEO Lanfear planning to issue more stock in mid-Oct after sure thing pop pre announce 3Q channel stuffed Cimeri sales not chancing to wait for high risk event of FDA Tori decision . Thats why Landfear is dragging on Tori clinic inspections"
X Link 2023-09-14T21:30Z [----] followers, [--] engagements
"#Econtwit #PBMs quiz: How might Akerlofs paper Market for Lemons apply to GPO-facilities formulary position market with mix of commercial and Part B patients And cause of ASP decline upon #biosimilar entry"
X Link 2023-09-17T17:36Z [----] followers, [---] engagements
"Hey @john_waynez -- your tweet "hope" that $CHRS would " slow sto potentially turning positive" after bouncing off lower end of the bollinger band on the 19th has not materialized.broke thru today.🤷♂"
X Link 2023-09-21T19:30Z [----] followers, [----] engagements
"@scooter88153165 No but efficacy and persistence is more complicated than simply targeting. This is screenshot from opening address of NK2023 meeting starting today in Oslo Norway. Here is a pdf of the program"
X Link 2023-09-26T17:36Z [----] followers, [---] engagements
"@iskander @AaronGoodman33 EMR is the largest SaaS untapped profit market out there. There will be challenger to EPIC. Slow but steady it will be $AMZN dogfooding a new EMR system with its recent acquisition of One Medical"
X Link 2023-09-28T03:45Z [----] followers, [--] engagements
"@RolfeNeelsen Based on todays $CHRS announcement of 100K dosages to date of Cimerli and 50% gross to net I have 3Q sales at $40M . Udencya also est. great net sales at $45M . Total net 3Q $85M. Short of your est $100M. Impressive but bad $XBI market and funds sour on CEO oncology strategy"
X Link 2023-10-04T16:06Z [----] followers, [---] engagements
"@UCPrezDrake time to investigate UCSC Dept. of Race & Ethnic Studies and two profs Christine Hong and Jennifer Kelly sponsoring an anti-Zionist conference in #SantaCruz Registration required signing these points of unity. Too many UCSC profs spreading hate against Israel"
X Link 2023-10-11T01:25Z [----] followers, [--] engagements
"CA State Senator John Laird: time to investigate UCSC and two profs Christine Hong and Jennifer Kelly sponsoring an anti-Zionist conference. Registration required signing these points of unity. Too many UCSC profs spreading hate against Israel"
X Link 2023-10-11T01:31Z [----] followers, [---] engagements
"@AmherstCollege President Elliott - your silence is defining regarding Hamas terrorist acts against Israel"
X Link 2023-10-11T02:25Z [----] followers, [---] engagements
"@MattBiotech We are close. We use different envelope math: me $44M 3Q net for Cimerli you $40M 3Q net. need to follow @Biohazard3737 quarterly posting of Symphony data (which only big time investors him can afford to buy) to get a more accurate estimate of gross WAC sales of $CHRS drugs"
X Link 2023-10-13T17:23Z [----] followers, [---] engagements
"@andrewpannu Need to consider IP and patent extension via at home sub-Q and on-body injections of original Dr office infused drugs. One problem is this changes management from insurance Co and Part B to Big [--] #PBMs and Part D more aggressive rebate negotiations"
X Link 2023-10-19T16:34Z [----] followers, [---] engagements
"@DaytonPubPolicy Better Central Cali schools put more money in competitive sports indigenous to area: surfing skateboarding rock fishing frisbee golf bike racing rock climbing"
X Link 2023-10-21T19:22Z [----] followers, [--] engagements
"@JWurzak Related questions: what next West Coast towns with indie vibe benefiting from WFH and urban doom loop: my picks (1) Bellingham WA (2) Paso Robles CA (3) San Luis Obispo CA (3) Mt Vernon WA (4) Bayside / Los Osos CA. Coffeehouses in Bellingham WA filled with Microsoft WFH"
X Link 2023-11-05T18:25Z [----] followers, [---] engagements
"@JWurzak @AlliedCRE Wrong. There are a number of Central Cali towns with indie vibe benefiting from WFH and urban doom loop: Paso Robles San Luis Obispo (3) Bayside / Los Osos (4) Atascadero (4) Templeton. Coolest coffeehouse in Central Cali is AMSTRDM in Paso Robles"
X Link 2023-11-05T18:53Z [----] followers, [--] engagements
"Pegfilgrastim #biosimilar market now brutal after [--] years with 5+ entrants: $CHRS just reported 3Q23 market share for Udenyca 🔼 big QoQ from 12.3% to 16% yet sales 🔼 only $31.7 M to $33.0 M cuz total market Q 🔽.(why post-COVID bump in ops over) and net prices continue to 🔽"
X Link 2023-11-06T22:51Z [----] followers, [----] engagements
"@ej23ny @user889889 No Big Pharma not buyout candidate for $CHRS as they now see #biosimilars market no longer as a high touch / high profit biologics market as CEO Landfear did in [----] but more as a small molecule generics race to the bottom pricing strategy of gaining market share. 1/2"
X Link 2023-11-09T21:51Z [----] followers, [---] engagements
"@ej23ny @user889889 Inflection point has been the market killing doom loop pricing strategy of Sandoz with Ziextenzo - increasing market share of non-OnPro market from 6% to 22% eliminating channel marketing costs and going with doom loop ASP drop of 50% in [--] years now at 1/2 ASP of Udencya"
X Link 2023-11-09T22:07Z [----] followers, [---] engagements
"No Existential moment for biosimilars market as WS no longer sees it as high touch play nice price disciplinebiologics market as CEO Landfear argued for $CHRS in [----] but a race to the bottom small molecule generics market 1/2"
X Link 2023-11-09T22:14Z [----] followers, [---] engagements
"Inflection point for change in view of #biosimilars market has been the successful doom loop pricing by Sandoz for Ziextenzo - gaining Non-OnPro market share from 8% to 22% in [--] years foregoing channel marketing expenses for 50% ASP price drop now 1/2 that of $CHRS"
X Link 2023-11-09T22:21Z [----] followers, [---] engagements
"Biosimilars market no longer a high touch price discipline market as Landfear argued in [----] as early entrants now subject to "doom loop" pricing pioneered by Sandoz with Ziextenzo. Will spread causing Cimerli revenue to fall after mid-2024. $CHRS [----] projections f***ed"
X Link 2023-11-10T03:06Z [----] followers, [----] engagements
"Here is a pix of Sept [----] graph where $CHRS was placing $1.2B revenue projection at end of graph"
X Link 2023-11-10T03:55Z [----] followers, [---] engagements
"As seen above the core belief of $CHRS that their "biosimilar cash flows support development of I-O pipeline" has been shattered by slight 3Q23 revenue miss due to Udenyca price erosion to fend off "doom loop" pricing by Sandoz. Company faces an existential crisis"
X Link 2023-11-10T04:07Z [----] followers, [---] engagements
"The big [--] drugstore chains $CVS $WBA and bankrupt Rite-Aid had the chance to diversity into high end cosmetics- now while their front of stores struggle the Black Friday crowds are flocking to Sephora and Ulta"
X Link 2023-11-24T20:33Z [----] followers, [---] engagements
"$CVS Caremark moving to cost + reimbursement for fill by retail pharmacies really is a signal that this source of #PBMs gross profits was small and now declining. Majority of biz model now is formulary rebates and channel sales markup on medical benefit specialty biologics"
X Link 2023-12-06T19:12Z [----] followers, [---] engagements
"One less UCSC faculty member of extremist Institute for the Critical Study of Zionism at @UCSC whose members organized antisemitic rallies on campus"
X Link 2023-12-10T22:25Z [----] followers, [---] engagements
"@MattBiotech Agreed $CHRS [----] revenue will be good. You at $520M me at $470M. But problems after 2Q24 as more biosimilar entrants drive net prices down. Stock price already reflects [----] revenue target of $1.2B is kaput and tepid cash flow positive not enough to fund IO pipeline"
X Link 2023-12-20T21:07Z [----] followers, [---] engagements
"@stocksdd @MattBiotech What revenues they gain via Udenyca OBI in 2H24 they lose back via really intense price competition and some share loss in PFS pegfilgrastim market. Plus and a couple a new entrants to ranibizumab market will cause Cimerli revenue decline starting 2H24"
X Link 2023-12-27T07:07Z [----] followers, [---] engagements
"@zohmbastic Read the fine print Zohmbastic Yes $CVS will prefer Humira biosimilars over Humira in [----] - but NOT from $CHRS but from Sandoz and Biocon"
X Link 2024-01-03T23:04Z [----] followers, [---] engagements
"@guptavinay These are powerful drugs with potential serious side effects. Best prescribed in person by PCP with ongoing relation rather than online Dr working from who knows where. $LLY is asking for trouble"
X Link 2024-01-05T18:19Z [--] followers, [--] engagements
"@StanMehr Success of #biosimilars markets should measured by net prices not WAC or market share. Better to have a single drug dominate at 80% off WAC than [--] drugs share market at 40% off. $ABBV rebating as much as $15 Billion to payers who have to use to lower premiums to keep within MLR"
X Link 2024-01-11T03:22Z [----] followers, [--] engagements
"@Space_Force__ @PharmaPinkSheet Agreed $LLY LillyDirect for its own self-injectables and small molecule drugs is not a threat to #PBMs but its UX featuring direct-to-consumer delivery via @truepill API pharmacy- as-a-service is another blow to bricks & mortar pharmacies. $CVS $WBA $RAD"
X Link 2024-01-15T23:08Z [----] followers, [---] engagements
"$CHRS followers need to look at [--] balance sheet items: (1) calculate days receivable = (Accounts Receivable ( 92% from Big [--] Distributors) / 3Q23 Net Revenue but add back off invoice rebates) * [--] . You will Lanfear still inflates sales by channel stuffing"
X Link 2024-01-16T23:13Z [----] followers, [---] engagements
"$CHRS balance sheet item (2) look deep into latest 10-Q and see they broke inventory down by expectations for useage. Turns out they estimate 1/2 wont be used until after [----] due to way too much Yusimry purchases relative to tepid sales expectations in 2024"
X Link 2024-01-16T23:21Z [----] followers, [---] engagements
"@jfais20 $CHRS No sufficient operating cash flow til maybe mid-2025 to internally finance trials with Tori and internal OI . Will require re-licensing to someone else at % and milestone payments above what they are obligated to pay Junshi See below. Net difference in % is problematic"
X Link 2024-01-19T17:18Z [----] followers, [---] engagements
"@jfais20 In short $CHRS is between a rock and a hard place to finance new trials with Tori - where rock is insufficient internal cash flow til maybe after mid-2025 and hard place is re-licensing Tori at material % of net sales greater than the original 20% they have to pay Junshi"
X Link 2024-01-19T17:36Z [----] followers, [----] engagements
"@StanMehr @stocksdd @MattBiotech Decision-making re: #biosimilars trials trivial compared to full [--] phase RCTs of combo oncology drug: (1) What SoC to use for control arm (1) What endpoint -PFS vs OS Also years before cash flow: $CHRS won't see cash from new USA Tori combo trial till mid-2027 to 2028"
X Link 2024-01-22T23:14Z [----] followers, [---] engagements
"@stocksdd @StanMehr @MattBiotech Key to achieving your total $CHRS pegfilgrastim revenue of $250M in [----] is what share it can get in OBI segment. I have them needing 25% share to get your number. Is that doable Yes with 20% rebate off WAC and $AMGN slow to follow. It all depends on how slow $AMGN responds"
X Link 2024-01-23T05:08Z [----] followers, [---] engagements
"@stocksdd @StanMehr @MattBiotech Per CMS: there are / will be no separate J-Codes and ASPs for OBIs vs prefilled. There is only one drug J-Code for both - J2506 - but [--] separate codes for Dr admin - CPT code [-----] for prefilled and CPT code [-----] for OBI. Not good for $CHRS"
X Link 2024-01-24T00:51Z [----] followers, [---] engagements
"@stocksdd @StanMehr @MattBiotech From CMS here is a screenshot of coding -- [--] codes for Dr admin -- prefilled vs OBI - and only [--] code option for drug. Not good for $CHRS as OBI market not insulated from price competition in the prefilled market"
X Link 2024-01-24T00:58Z [----] followers, [---] engagements
"While the #biosimilars market began in [----] it wasn't until [----] that price competition started to take off What changed Yes to Govt policy and # of entrants. IMHO another factor has been divestiture by "white shoe" old-line $NVS $PFE $MRK to cos with a generics mind-set"
X Link 2024-01-30T03:21Z [----] followers, [---] engagements
"Starting to see the wisdom of $CHRS CEO Landfear in selling off Cimerli as "non-core" Why Back in 2020-21 he saw that old-line "white shoes" Pharma $MRK $NVS $PFE were selling off their #biosimilars to cos with a generics price competition mindset"
X Link 2024-01-30T03:33Z [----] followers, [----] engagements
"With the disappointing launch of $AMGN Humira biosimilar and the delayed launch of its Eylea biosimilar and seeing other old-line Pharma $MRK $PFE $NVS divest their #biosimilars lines to co with generics price competition mindset I expect $AMGN to divest also within a year"
X Link 2024-01-30T03:54Z [----] followers, [---] engagements
"The Big [--] #PBMs [----] formulary for Humira and its #biosimilars is indicative that choice is based on the product of net unit price * expected demand (where brand and marketing clout matters) not just net price. This is why small co $ALVO $OGN $CHRS will never be chosen"
X Link 2024-02-07T20:15Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing